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ABSTRACT




Dr. David M. Hassenzahl, Committee Chair 
Chair, Department o f Environmental Studies 
University of Nevada, Las Vegas
Unused pharmaceuticals take an unhealthy toll on both the environment and human 
health. In the US alone, an estimated $1 billion of prescription drugs are thrown away 
eaeh year. Increasing availability, marketing, and purchasing of both prescription and 
over-the-counter medications, coupled with the tendeney of patients to discontinue use of 
and to stockpile drugs at home, is a unique problem that has garnered inereasing attention 
among seientists, policymakers, and the media in the last ten years.
These aceumulated household drugs beeome unused pharmaeeutical waste. This 
w aste m ust be disearded and disposed o f  by  the consum er. H istorically, consum ers have 
been instrueted by health care professionals to dispose of unwanted medieations into the
111
sewage system. Inserts in some pharmaeeutieal paekaging have also instrueted eonsumer 
to flush expired and unused medications down the toilet. This method has historically 
also applied to pharmaceuticals stored in locations other than the consumer household.
In the past decade studies have consistently identified amounts of pharmaceutical 
residues in water systems throughout the country. However, it has yet to be determined if 
the source of these substances found in the waterways is from excretion or disposal. 
While it is most likely a combination of both, it has been difficult to assess to what extent 
disposal takes place. Namely, there has been no source of data that would convey how 
often disposal takes place, what are the more common pharmaceutical compounds 
disposed, and in what quantities these compounds are flushed into our sewage systems.
This dissertation deseribes a new methodology -  eompiling inventory data from 
coroner offices -  which can provide a source of data detailing exactly how much of a 
specific pharmaceutical ingredient has been disposed in a particular geographic area and 
the frequency with which that compound is found in the disposal inventories. Further, 
this work assesses the many, varied, and often overlooked sites of accumulation of 
unused medications, the approximate relative contributions generated at each site, and 
common reasons why they accumulate in their respective locations. Finally, this work 
assesses the risk associated with inappropriate transfers of pharmaceuticals, and potential 
means for mitigating the risks.
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The occurrence of traee levels of pharmaeeutieals in the environment ean be the result 
of intended use, via excretion or bathing, or disposal of the drug via either the toilet or the 
trash. Every pharmaeeutieal ingredient has its own pharmaeokinetie profile that will 
dietate how mueh of the parent drug, or one its metabolites, will be exereted by both the 
kidney and the bowel. Bathing ean result in transfer of some compounds to the 
environment from use of topically applied medieations.
Disposal represents a direct introduction of the parent eompound into the 
environment. This transfer into the environment oeeurs following the non-use of the drug 
as it was originally intended, either by preseription or by its storage in a partieular site. 
For example, expired drugs from first-aid kits are routinely flushed and replenished.
Pharmaeeutieals go unused for a variety of reasons. Patients may voluntarily 
diseontinue therapy due to expiration, adverse efleets, side effeets, ehange in medieation 
regimen, or poor pereeption of the extent of illness. Studies report 15% of all hospital 
admissions in 2003 were due to poor eomplianee or eomplete eessation of therapy (Gold 
and MeClung, 2006). Poor adherenee has been estimated to eost approximately $177 
billion annually in health eare eosts (NCPIE, 2007). A reeent survey found that 49% of 
respondents admitted to forgetting to take their preseribed medieation (NCPA, 2006).
This can lead to an inordinate amount of stockpiling of medications in the home -  all of 
which ultimately have to be disposed of.
If the drugs were not to be disposed and instead are allowed to aeeumulate in their 
respeetive loeations, the eoneem is the eonsequent availability for inappropriate usage of 
the drugs -  either intentionally or unintentionally. There is often a false sense of safety 
with pharmaeeutieals. They are ubiquitous, sold in pharmacies, and prescribed by trusted 
physieians. Drugs are often left unseeured. The Ameriean Assoeiation of Poison Control 
Centers reports that there were approximately 1.5 million pharmaeeutieal exposures 
reported to poison eontrol centers in 2004 (Watson, 2005). An exposure, as defined by 
the AAPCC, refers to an inquiry made to a eertified poison eenter regarding the 
unintended use or eontaet with a preseribed medieation. Almost 2,500 of these exposures 
resulted in death. The National Center on Addietion and Substanee AbUse reported a 
212% inerease in the use of eontrolled drugs by teenagers between 1992 and 2003 
(CASA 2003).
The disposal pathway for unused medieations is governed by preseription praetiees 
and personal behavior. There are two main routes for pharmaeeutieals to enter the 
environment. The first is through normal usage o f medieines. After administration, a 
quantity o f the drug, or its metabolites, is exereted from the body. The pharmaeokinetie 
profile of the drug, the dosage consumed, the physiology of the individual, and the 
efficieney of the wastewater treatment governs release and eventual exposure via this
I
pathway. When a person eonsumes a medieation, depending upon the ehemieal strueture, 
metabolism, and bioehemical interaetion of the drug, as well as some gerietie variability 
in physiology, the drug may be either transformed (yielding one or more metabolites)
which are then released from the body, or excreted unaltered with its chemical structure 
intact.
The second route by which pharmaceuticals can enter the environment, and the focus 
o f this research, is the disposal of out-of-date, unused, or unwanted medicines, which 
may occur via the sink/toilet or in household garbage that is then taken to landfill sites. 
Entry into the environment by this route depends on the habits o f the patient and the 
efficiency of prescription practices leading to fewer unfinished prescriptions.
Kuspis and Krenzelok (1996) reported that only 1.4% of Americans surveyed 
returned unused medication to the pharmacy, whereas 54% threw them in the trash, and 
35.4% disposed of them in the sink/toilet. For most people, household garbage is the 
most straightforward and least time-consuming method of disposal. Even if the return of 
all pharmaceuticals to a pharmacist or a physician were legal, there is no monetary 
incentive to return medicines to the pharmacy and it requires more effort than simply 
discarding them. There would have to be another motivating factor employed to entice 
the public to participate in a return system of their unused medication.
The question of how to dispose of unwanted and unused pharmaceuticals is proving 
to be a daunting task. Historically, consumers have been directed by healthcare 
professionals (i.e., doctors and pharmacists) and poison control centers to flush the 
medications down the toilet, then pour them down the sink, or throw them into household 
trash. US Drug Enforcement Administration (DEA) regulations strictly control the 
transfer o f drugs that are controlled substances under the Controlled Substances Act 
(CSA) (US DOJ, 1970). The CSA was enacted into law by the Congress of the United 
States as Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970.
This law prohibits the transference o f any eontrolled substanee from the prescribed 
individual to any entity other than law enforeement. The eonsumer is considered the end 
user and eannot transfer the eontrolled medieation to anyone, ineluding a physieian or a 
pharmaeist. This is one of the reasons that most pharmaeies will not accept returns from 
patients.
Abuse of prescription analgesics in 2007 ranks second— only behind marijuana— as 
the Nation's most prevalent illegal drug problem (ONDCP, 2008). In an effort to eombat 
the rising rates of preseription drug abuse, the White House Offiee of National Drug 
Control Poliey (ONDCP, 2007) has established the first Federal guidelines for proper 
disposal of unused drugs. These guidelines, released in February 2007, direet consumers 
to adulterate unwanted medications by mixing with an unpalatable substanee and then 
disposing into the household trash. Yet the guidelines also inelude a list of medications 
with either a perceived or known risk of diversion and toxieity. In order to avoid potential 
publie health eonsequenees, consumers are instrueted to flush these medieations to ensure 
they are not available to those who are inelined to sort through public trash or to those 
who might aeeidentally ingest them, sueh as toddlers or pets.
Environmental and Human Health Impaets
The unexamined disposal of unwanted medieations has led to eoneem with regard to 
the health of the environment beginning in the 1970’s when seientists began to reveal the 
ability of pharmaceuticals to enter the environment. Garrison et al. (1976) first reported 
elofibrie aeid (the aetive metabolite from the lipid regulators elofibrate, etofibrate, and 
theofibrate) in raw sewage and aetivated sludge effluent. Hignite and Azamoff (1977)
reported the detection o f salicylic acid and other drug metabolites in the influent and 
effluent of a sewage treatment plant in Missouri. A landmark monitoring study published 
in 2002 by the United States Geological Survey (USGS, 2002) found that 80% of 139 
streams sampled across 30 states detected (albeit at low concentrations) chemicals 
commonly found in prescription drugs.
In waterways from the Potomac to the Brazos River in Texas, researchers have found 
fish exposed to trace levels of estrogens and antidepressants, and many show evidence of 
neurological or physiological changes (Folmar et ah, 16; Ying, 2008). Several studies 
have demonstrated detrimental effects on fish species such as alterations in sex ratios, 
other endocrine disturbances, and abnormal social behaviors (Cleuvers, 2004; Fent et ah,
2006y
Advances in analytical chemistry enable us to irrefutably decipher residues of 
pharmaceuticals in the environment. Detection of chemical compounds at concentrations 
of parts per billion and parts per trillion are now possible (Hirsch et al. 1999). A recently 
published study in the Netherlands concluded, based on calculated hazard quotients, the 
effects o f fluoxetine, ibuprofen, and carbamazepine, three very commonly prescribed 
drugs, place the “environment at risk” (De Lange et al., 2006).
The assessment of detrimental and deleterious effects on the environment includes 
not only an understanding of the chemical and biological interfaces, but also o f the 
sources from which the chemicals come. Accumulation of pharmaceuticals occurs at 
many different points in our communities. The sources of pharmaceutical accumulation 
are the end sites of the drugs -  the location they may be found prior to their disposal or 
perpetual storage. Regardless of the method of disposal, commonly prescribed
medications leave the manufacturer for a fate of either consumption or non-consumption. 
Non-consumed drugs end up in many sites, including schools and child care facilities, 
hospitals, nursing homes, hospice eare centers, doctor and dentist offices, public use first 
aid kits, veterinarian offices, farms, military bases, and prisons (Ruhoy and Daughton, 
2008).
That pharmaceutical chemicals found in the environment pose a substantial threat to 
human life is a natural assumption. Data on long-term impacts on human health is limited 
and varied, but some evidence does seem to point to potential effects. Epidemiological 
research designed to explore causality of illness has produced increasing evidence that 
exposure to toxic agents contributes to the escalating burden of human chronic affliction 
(Hu, 2003; CDC, 2005). Most pharmaceuticals are designed to target specific molecular 
structures on human cellular receptors. Many receptors are evolutionarily conserved. 
Their structure and design are ubiquitous among humans as well as across many different 
species.
A definitive understanding of the relationship between the disposal of 
pharmaceuticals and environmental impacts still eludes us. The chasms of knowledge 
with respect to amounts, sources, and interactions stalls the implementation o f policy to 
guide the disposal of drugs that are not used as originally intended. A common 
controversy is the relative contributions o f disposal and human excretion to 
pharmaceutical residues found in the environment. It is not currently known what
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portions of the pharmaceutical ingredients found in the environment originate from 
human disposal.
On a basic level, the extent o f disposal of unused medications is poorly documented. 
An evaluation of human disposal would include rates of prescription and rates and 
degrees o f non-compliance of the most commonly prescribed medications. Non- 
compliance, referring either to the complete cessation of medication consumption or an 
alteration to the original treatment plan as directed by a health care practitioner, rates are 
difficult to assess, however, and the literature often reports varying rates depending upon 
the disease treated and the treatment used (see Demyttenaere et ah, 2008; Home, 2006; 
Rains et ah, 2006). Even so, an assessment o f medication disposal would have to assume 
a certain percentage of consumers dispose of the dmgs while others simply accumulate 
unused.
While the precise chemical structure o f the drugs entering the environment is well 
known for those instances of disposal, we would still need to further our understanding of 
its effects on the environment including its retention in our waterways. Currently, our 
wastewater treatment works are not equipped to remove all pharmaceuticals, or their 
metabolites. Studies have shown that many pharmaceuticals are not fully removed by 
sewage treatment systems (Petrovic and Barcelo, 2007). In addition, a comprehensive 
environmental risk assessment would have to include a spectrum of alternative dose- 
response relationships, such as the potential synergistic and/or additive effects among the 
chemicals.
The literature on pharmaceuticals in the environment has exponentially increased 
during the past decade. The research has mainly focused on the detection and 
quantification of pharmaceutical compounds found in natural resources as well as some 
theoretical examination o f the correlation between these compounds and the
physiological alterations and aberrations reeently seen in aquatie life. There is seant 
literature on the reasons and amounts of drugs that are disposed and whether this disposal 
is at all responsible for the concentrations reported in the environment.
This dissertation analyzes the problem of where, how much, and why 
pharmaceuticals accumulate where they go unused. This issue has garnered attention by 
many, often competing, interests and factions. One objective is to design a complete 
assessment of unused pharmaceutical chemicals and the extent and result of their 
disposal. This contributes to the growing body of knowledge as we begin to understand 
the extent to which drugs accumulate in our society and then in our natural environment. 
An ultimate goal would be to foster practices that would lead to reducing the amount of 
leftover pharmaceuticals, primarily by improving prescription and dispensing behaviors 
as well as patient compliance. An understanding of the factors governing usage and non- 
compliance would help to drastically reduce the amount of leftover drugs. To improve 
patient compliance in the US would not only decrease the quantity of medications to be 
disposed of, since they would be consumed instead, but would also increase the 
physician’s ability to treat and thereby improve patient outcomes. The continuing surge 
of prescription rates likely leads to both an increase in use o f the drugs and to an increase 
in non-use.
The pharmaceutical industry continues to develop new molecular entities and, 
perhaps more importantly, introduces thousands o f new formulations and patents on 
existing chemical entities each year, using isomers o f chemical structures already used in 
clinical medicine. The approval process for new drugs and the post-marketing safety 
surveillance is fraught with flaws and inadequacies (Michaels, 2008). While these
medications certainly save and improve human lives, the irresponsible and unregulated 
prescribing of these compounds results in waste. If  we are to create a sustainable 
healthcare system, the environment should be protected from increasing advancements in 
and continual changes in pharmaceutical chemicals that are not used as intended and 
subsequently enter the ecosystem, which has not necessarily evolved to withstand the 
consistent and chronic introduction of toxic foreign compounds. Our environment is 
resilient but can we expect it to continue to withstand and endure further burden? This 
will require all those involved in the development, manufacturing, distributing, 
prescribing, regulating, and utilizing these pharmaceutical chemicals to collaborate to 
devise a plan to better manage the perception, reception, acceptance, and use o f drugs in 
this country.
This dissertation estimates amounts of releases (Chapter two), the range of 
accumulation locations in society (Chapter three) and mitigation strategies including 
pollution prevention (Chapter three) and four-stage risk management (Chapter four). It 
concludes in Chapter five with a discussion on the impact o f this research and 
recommendations for not only future research but for a renewed approach to greener 
healthcare.
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TYPES AND QUANTITIES OF LEFTOVER DRUGS ENTERING 
THE ENVIRONMENT VIA DISPOSALTO SEWAGE -  
REVEALED BY CORONER RECORDS
Overview
Pharmaceuticals designed for humans and animals often remain unused for a variety 
of reasons, ranging from expiration to a patient’s non-compliance. These leftover, 
accumulated drugs represent suboptimal delivery of health care and the potential for 
environmentally unsound disposal, which can pose exposure risks for humans and 
wildlife. A major unknown with respect to pharmaceuticals as pollutants is what fractions 
of drug residues occurring in the ambient environment result from discarding leftover 
drugs. To gauge the significance of leftover pharmaceuticals as potential pollutants, data 
are needed on the types, quantities, and frequencies with which these drugs accumulate. 
Absence of these data has prevented assessments of the significance o f drug 
accumulation and disposal as a contributing source of pharmaceutical residues in the 
environment. One particular source of drug accumulation is those medications that 
become "orphaned" by the death of a consumer. A new approach to acquiring the data 
needed to assess the magnitude and extent of drug disposal as a source o f environmental 
pollution is presented by using the inventories of drugs maintained by coroner offices.
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The data from one metropolitan coroner’s office demonstrates proof of concept. 
Coroner data on leftover drugs are useful for measuring the types and amounts of drugs 
aeeumulated by eonsumers. This inventory also provides an aeeurate measure o f the 
individual aetive ingredients aetually disposed into sewage by eoroners. The types of 
questions these data ean address are presented, and the possible uses o f these data for 
deriving estimates of source eontributions from the population at large are diseussed. The 
approaeh is proposed for nationwide implementation (and automation) to better 
understand the significanee of eonsumer disposal o f medieations. Note: This ehapter has 
been previously published as Ruhoy and Daughton 2007.
Introduetion
Understanding the seope and magnitude of medieation disposal is required for 
providing: (1) more aeeurate and eomprehensive data for models used for predicting 
amounts or concentrations o f active pharmaeeutical ingredients (APIs) introduced to the 
environment, and (2) a better understanding o f the prescribing, dispensing, and eonsumer 
consumption practices that lead to the aeeumulation of leftover (unwanted or unneeded) 
drugs and which then eontribute to human morbidity and mortality via poisonings 
(Watson et ah, 2005). There are two major reasons that leftover drugs are not 
immediately disposed: (1) inadvertent household accumulation (resulting from drugs 
languishing unnoticed past their expiry), and (2) purposeful stockpiling (because the 
consumer is awaiting a satisfactory means for disposal) (see Figure 1).
This chapter introduces a methodology for collecting data to provide evidenee-based 
estimates on the types and quantities of APIs disposed to the environment. While still
13
rarely used, the records o f  coroner offices for use in epidemiologic research has been 
evaluated and recommended by Conroy and Russell (1990). Coroner offices in many 
locales maintain detailed inventories of medications remaining at sites visited for 
investigation and acquisition o f decedents. Drug stockpiles can serve as a means of 
obtaining maximum and minimum ranges on the quantities and types o f drugs that might 
have ordinarily been disposed by this subpopulation. These inventories also become an 
accurate record o f the types and quantities o f APIs that are actually disposed by coroner 
offices. This is the first time that an extensive dataset of disposed drugs has been 
compiled for a well-defined population whose sewage is known to be handled by 
particular sewage treatment facilities. Such a dataset should permit calculations of 
average (or minimum) concentrations of APIs introduced via sewage. This is proposed as 
a general approach that can be widely implemented. The pieces o f data, namely, types, 
dosages, and quantities of remaining pharmaceuticals, collected using this new approach 
are useful for quantifying or estimating source contributions of pharmaceuticals 
introduced to the environment and which subsequently could play roles in ecological as 
well as human exposure, via the natural or artificial recycling of water.
Residues of a wide array o f pharmaceuticals are known to occur as contaminants in 
the environment (Daughton and Temes, 1999; Halling-Sorensen et al., 1998; Kolpin et 
al., 2002). A major research gap continues to be an understanding of the relative 
contributions to these ambient residues resulting from their intended use (such as from
i
excretion and bathing) versus the direct disposal of unwanted, leftover,medications. The 
significance of contributions from direct disposal compared with excretion remains
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controversial, largely because there have been no easy means of determining the 
quantities of medications that are directly disposed, for example to sewage or trash.
The topic of pharmaceuticals as environmental pollutants continues to foster 
increasing discussion and debate. Various groups, including regulatory agencies, 
independent organizations, water utilities, and public advocacy groups, have placed high 
priority on determining whether the existence of APIs in the environment, albeit at low 
concentrations, pose exposure risks for humans or the environment (Pent et ah, 2006). 
One of the outgrowths of this concern in the US has been increasing interest from local 
and regional agencies in the implementation of programs designed to take back 
medications stockpiled by consumers, thereby obviating their disposal directly to the 
environment. Several states, cities, and counties have successfully implemented both 
single and recurring collection events for unwanted medications (IISG, 2007). The 
intention of these "take-back" programs has been to reduce the introduction of APIs to 
sewerage and trash, from where they can enter the environment as contaminants. The key 
unknown with these pollution prevention efforts, however, is whether they can 
significantly reduce the individual or overall loadings of APIs to the environment 
(Daughton, 2007).
An additional development is the recent federal guidelines for drug disposal. In an 
effort to combat the rising rates of prescription drug abuse, the White House Office of 
National Drug Control Policy (ONDCP, 2007) has established, along with the US EPA 
and the FDA, the first Federal guidelines for proper disposal of unused drugs. These 
guidelines, released in February 2007, direct consumers to adulterate unwanted 
medications by mixing with an unpalatable substance and then disposing into the
15
household trash (except those few whose labels require disposal to sewage because o f the 
acute risk of diversion resulting in human poisonings). While adulterating medications in 
this manner does not remove the API’s potential to enter the natural environment, the 
intent of these reeommendations is to prevent purposeful introduetion of medieations into 
sewage while also rendering them unpalatable for those who attempt to reclaim the drugs 
from the trash for inappropriate use. The federal guidelines also suggest returning 
leftover drugs to local “take-back” locations, when available. This demonstrates the 
Federal government’s interest in reducing the availability o f drugs to those who seek to 
misuse or abuse prescription medication, while also redueing environmental pollution.
Pharmaceuticals are ubiquitous eompounds that have the ability to alter innate human 
physiological mechanisms. Studies of these compounds as they occur in the environment 
are unique in various ways. First, these compounds are often detected at such low 
concentrations (ng L"') that detection is usually limited to more recent, advanced 
analytical techniques employed at research laboratories (Daughton, 2007). Second, recent 
studies (e.g., Heberer, 2002; Radjenovic, 2006; Snyder et al., 2006) have indicated 
efficient and effective methods (e.g., ozone oxidation) o f removing, if  not all detectable 
amounts, a significant percentage of the more commonly studied APIs; note, however, 
that “removal” can refer to the structural transformation of the API or it can simply refer 
to the physical relocation or partitioning of the API from the aqueous phase to the solids 
(sludge) phase. It is important to note that most wastewater treatment plants (WWTPs) in 
the US do not possess the resources required for the best available treatment technology. 
Third, controversy remains over whether acute or chronic exposure to pharmaceuticals in 
our water supply results in detectable human health effects. Finally, and with reference to
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the study presented here, while there have been a number of studies that have measured 
levels of APIs and their metabolites in wastewater, there has been no ready source o f data 
that characterizes the types and masses of APIs disposed via flushing to sewage and 
whether these amounts are significant with respect to overall environmental loadings 
(Daughton 2007).
Chemical monitoring studies have provided evidence of the presence of drugs in the 
aquatic environment (e.g.. Pent et al., 2006; Heberer, 2002; Hignite and Azamoff, 1977; 
Hirsch et al., 1999), and less frequently in drinking waters, but the sources and their 
correlations with disposed quantities have proved difficult to determine. There are no 
datasets that elucidate categories and quantities of drugs that are disposed at any 
particular time. Coroner offices, however, consistently compile drug disposal data during 
the ordinary course of investigating and taking custody of the bodies o f decedents for 
each coroner case. A survey of this inventory provides a snapshot and some insights as to 
the potential extent of unused pharmaceuticals and their disposal. The information 
gleaned from these under-recognized databases can help guide the identification of drugs 
to be monitored in the environment and better target where pollution-prevention or 
source-control efforts should be directed.
Often overlooked are other important possible uses from obtaining comprehensive 
data on leftover drugs and their disposal. Such data could foster the optimization of 
prescribing and dispensing practices within the healthcare communities, along with 
improving communication with patients to improve their adherence to medication 
regimes. This transformation, by reducing leftover medications, would lessen the 
consequent need for disposal, and possibly improve healthcare outcomes (Daughton,
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2003a). In the ideal world, perfectly functioning prescribing and dispensing systems, 
coupled with perfect medication adherence by the patient (while noting that one cause of 
non-adherence is unanticipated adverse effects), would lead to zero drug wastage and 
completely eliminate the need for disposal of leftovers. Although probably not a 
realistically achievable goal, any progress in this direction might also improve the quality 
of healthcare.
The presence of pharmaceuticals in our environment is by no means unexpected. 
Pharmaceuticals owe their release to the environment to their universal and highly 
dispersed but cumulative usage by multitudes of individuals (Daughton, 2001). From 
1993 to 2003, the number of prescriptions purchased in the US increased 70% (from 2 
billion to 3.4 billion) (Kaiser, 2004), while the population increased only 13% (from 
257,782,608 to 290,796,023) (US Census Bureau, 2006). The elderly consume an ever- 
increasing number o f medications -  some prescribed to counteract the effects and 
responses of other prescribed medications. At any given time, 40% of those older than 
65 years use five or more drugs, and 50% of all adults in the US (greater than 18 years of 
age) take at least one prescription medicine (Kaufman et al., 2002). In 2005, among the 
300 most frequently prescribed pharmaceuticals in the US, more than 2.5 billion 
prescriptions were written (RxList, 2007). Prescription rates for opioids, 
benzodiazepines, diuretics, monoamine agonists, anti-infectives, and corticosteroids were 
the highest among all the medications prescribed.
Unused pharmaceuticals not only pose exposure risks for both the environment and 
humans, they also reflect lost opportunities for proper therapeutic treatment and wasted 
healthcare resources. In the US alone, an estimated $1B (US) of prescription drugs are
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discarded each year (Strom, 2005) from healthcare institutions such as hospitals, 
pharmacies, hospices, and long-term care facilities; figures for consumers do not exist. 
Although procedures are available in the healthcare sector (such as hospitals, pharmacies, 
hospices and long-term care facilities) for the proper disposal o f unused pharmaceuticals, 
especially for the low percentage that are regulated as hazardous waste, generally these 
substances are simply disposed to drains (and sometimes to trash) or disposed along with 
regulated medical waste (Burke and Smith, 2006). These unwanted and unused drugs 
represent a costly wasted resource for the healthcare system and indicate the growing 
problem of what to do with unused and unwanted medications or how to minimize their 
creation. With regard to public health, this wasted resource may reflect inefficiencies in 
prescribing practices and may indicate sub-optimal delivery o f healthcare, impairing or 
diminishing therapeutic outcomes. Unused, unwanted drugs in consumer homes 
inadvertently accumulate past expiry or are stockpiled (awaiting disposal) and are 
therefore available for those (including children) who seek to abuse them or who might 
ingest them accidentally (Figure 1, end of chapter). Unwanted drugs, moreover, represent 
a source from where a spectrum of biologically active anthropogenic chemicals can enter 
the environment. That human health and the health of the environment can be 
inextricably tied (Daughton, 2003b) is demonstrated perhaps in no better way than the 
fact that the non-optimum delivery o f health care is, in part, a contributing source for 
pharmaceuticals in the environment, which in turn may play a role in affecting the 
environment and, therefore, quality of life.
Prior to this approach described for mining coroner data, the only means available for 
obtaining inventories of drugs destined for disposal was from take-back events or from
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physical investigation of municipal trash. Both are highly resouree intensive, and as a 
consequence are o f limited informational value. Obtaining data from take-back events 
requires the efforts o f a pharmacist (under the vigilance of law enforcement) to identify 
and record the identity o f the medication, the dosage o f the API(s), and the dosage units. 
These data are already meticulously collected during the course o f coroner investigations, 
requiring no additional work.
Decedent populations could be biased in terms of age and health status. Many 
decedents are younger and probably represent the norm in terms of health and drug 
consumption. The drugs inventoried during coroner investigations could therefore 
possibly be biased in terms o f the types o f drugs or their formulations, and perhaps biased 
somewhat high in terms of the quantities on-hand (for those with declining health). In 
contrast, the drugs returned at local take-back events held on sporadic schedules very 
possibly represent accumulations over long periods o f time (where the consumer had 
accumulated a backlog o f drugs for an entire household while waiting to eventually find 
out how they could be disposed). This means that the quantities o f drugs initially received 
from a particular individual during a take-back event may be biased high -no t 
representing the amounts that would be returned if take-backs occurred on a continual 
basis; it is also very difficult to extrapolate to the general population. For the decedent 
population, the types and quantities of drugs on hand represent the types and amounts 
that would be found at any point in time for a decedent. For take-backs, however, the 
quantities o f drugs returned cannot easily be used to calculate population accumulation 
rates because the quantities that any one individual returns could decline over time. Data
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would need to be collected over sufficiently long periods o f time to obtain representative 
data.
Coroner investigations do not select for inherently biased populations - - namely 
individuals who were necessarily purposefully saving unwanted drugs. Most decedents 
had probably been living lives unconnected to any focus on accumulating drugs. In 
contrast, the population attending take-back events may be biased in terms of those who 
have purposefully been accumulating leftover drugs while waiting to figure out how to 
dispose o f them.
Another consideration with respect to coroner data is the ability to collect more 
information regarding the individual, such as age, sex, patient non-compliance, illicit 
drugs (usually available from police investigation reports), and location of residence. 
Location is important should it be desired to estimate quantities of APIs that are 
introduced to sewage within a particular sewage district [in order to calculate 
concentrations or quantities entering a given Wastewater Treatment Plant (WWTP)]. 
Compliance is extremely useful to know in order to better design approaches to pollution 
prevention, such as more vigilant and appropriate prescribing.
Attempts at identifying and quantifying the types and amounts of wasted drugs have 
often been inadequate in terms o f accuracy, consistency, and breadth. Most o f the 
information amassed has been from various one-time local take-back events (CRG 2006). 
Data collection from these events has never been standardized, and there is no current 
consensus on the most efficient way to inventory the types and quantities of drugs 
received over the course o f these events. Often reported are just the gross weight and/or 
volume of the complete, formulated medications, sometimes including the retail
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packaging (without note o f actual API content), because identifying and measuring the 
types and amounts of drugs was labor intensive and frequently cost prohibitive. The 
Unused Medicine Registry (CRG Medical Foundation, 2006) was recently established by 
the Community of Competence organization in Bellaire, TX to collect information about 
drugs remaining in the home. The Registry is designed to collect information from 
community-based drug return programs (take-backs) on the medications received from 
consumers. While the Registry demonstrates some important trends in unused 
medication, the data received are from a variety of events, many with different 
organizational structures and different methodologies used to collect the data. Another 
major limitation of data collected from take-backs is that the subpopulations o f those who 
return their medications cannot be correlated with the WWTPs that receive their waste, 
making calculation of API masses introduced to known sewage flows inaccurate or 
impossible. Other methods of acquiring similar types of data generally focus on waste 
from institutions such as hospitals and long-term care facilities, which are not necessarily 
representative o f the general population.
The methodology described here allows for the identification and quantification of 
the APIs actually disposed from a previously unrecognized but common source — coroner 
offices. Comprehensive data on medications disposed within one metropolitan county, 
Clark County, NV, during a calendar year were compiled. The information contained in 
the greater than 1,600 records includes not only the type of medication found, but the
i
number of pills remaining, the dosage amount of each pill, the date df the prescription, 
and the prescription directions such as the frequency of the directed consumption. These 
medications represented greater than 400 different active pharmaceutical ingredients.
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encompassing the more commonly prescribed cardiovascular and central nervous system 
agents to the less often prescribed such as anti-retroviral medications. The complete 
inventory of medications identified by the Clark County, NV Coroner Office will be 
published in future publications.
These data provide some insights and measures regarding the contribution to ambient 
environmental residues of human drugs that result from sewage disposal. If this type of 
data were to be collected on a nationwide basis, the means for improving the practices for 
prescribing and dispensing of drugs could eventually lead to minimization of the 
accumulation o f leftover drugs. A major outcome of this new methodology would be an 
increased understanding of the scope o f disposed pharmaceuticals. Such an understanding 
could lead to new approaches for reducing drug diversion, abuse, and accidental 
poisonings, as well for improving therapeutic outcomes at lower cost.
Background
It is considered standard protocol by most coroner offices in the US, as described by 
the National Association of Medical Examiners (NAME, 2007), that when a medical 
investigator from the coroner's office arrives upon the scene of a decedent, following the 
standard procedures regarding the approach to the body and the scene. The investigator 
will then search for medications, prescribed in the name of the decedent, present on the 
scene, in case drugs may have contributed to the cause o f death. There are some cities, 
however, where law enforcement services are called to the scene rather than investigators 
from the coroner’s office; in these cases, the coroner’s office medical investigator plays 
no role in analyzing or removing anything from the scene and therefore does not have
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any role in the disposal o f leftover medication -  they simply receive the expired body. 
There currently are no accessible statistics that describe how many cities primarily use 
law enforcement instead of coroner services, nor is the process of collecting and 
inventorying medications standardized among them. However, a survey is under 
preparation to effectively assess the prevalence o f coroner offices that operate under these 
guidelines (Ruhoy, in preparation).
A death becomes a coroner's case when the decedent has either expired alone or the 
death is considered suspicious by law enforcement. The majority o f the coroner cases are 
due to those deaths that occurred without a witness present. The investigator at the scene 
records the information found on the medication vial or submits them to Poison Control 
Services for help in identification. This information includes the prescription number (as 
labeled by the dispensing pharmacy), the date the prescription was filled, the name of the 
medication (generic or brand name), the dosage, the directions for taking the medication 
as prescribed by the physician, the prescribed number of pills (which refers to both 
tablets and capsules but does not include powders, liquids or alternative drug delivery 
systems), and the name of the prescribing health care professional. The final and 
important piece of information recorded by the investigator is the number of pills 
remaining in the prescription vial. A facsimile of a typical coroners’ site-investigation 
record is shown in Figure 2 (end o f chapter).
Following the collection of data on an inventory sheet, the investigator then disposes 
of the remaining prescription pharmaceuticals. This is done most often via the toilets at 
the locations of the decedents and always done in the presence of a witness. Occasionally, 
the medications are disposed of in the garbage of the home, either because of faulty toilet
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systems or at the request o f family. Disposal is manually recorded along with the 
signatures of the disposer (usually the investigator) and the witness (usually a family 
member or a local police officer). These factors all contribute to ensuring a high standard 
of quality for the collected data.
The medical investigators are “deputized” and, therefore, act as representatives of law 
enforcement. This is necessary due to US Drug Enforcement Administration (DEA) 
enforcement of the Controlled Substances Act (CSA) (US DOJ, 1970). The CSA was 
enacted into law by the Congress of the United States as Title II o f the Comprehensive 
Drug Abuse Prevention and Control Act of 1970. This law prohibits the transference of 
any controlled substance from the prescribed individual to any entity other than law 
enforcement (see summary in Daughton, 2007). The consumer is considered the end user 
and cannot transfer the controlled medication to anyone, including a physician or a 
pharmacist. All pharmaceuticals identified by the medical examiner are required to be 
disposed of by the investigator, as opposed to allowing family members to take 
possession of the leftover drugs. Law enforcement officers are permitted to seize 
controlled substances. It is permissible, however, for consumers to return unused and 
unwanted pharmaceuticals to their local police stations.
Medications collected and disposed of by coroner offices are themselves a 
measurable source of drugs in the environment. O f more interest, however, is the fact that 
these inventories provide information regarding the categories and dosage amounts of 
medications that accumulate and require disposal. At the least, if  local sewage flow rates 
are known, coroner disposal data can be used to calculate minimum known introductions 
to sewage for an individual water treatment plant or watershed; additional sources would
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include excretion and bathing, as well as disposal from a wide array o f additional sources, 
including consumers (Ruhoy and Daughton, 2008). For the purposes o f the model 
scenarios developed in this discussion, the assumption is that the sole source of an active 
pharmaceutical ingredient (API) in sewage would be from direct disposal by coroner 
offices. At the maximum, these data could be used to estimate upper boundaries for these 
introductions (by assuming similar drug disposal rates across a community’s entire 
population, not just from the coroner). The empirically measured load for any given drug 
targeted by a monitoring study o f sewage influent would fall below or near this imputed 
upper bound if  excretion were a minor source. An empirically measured concentration for 
a drug that is extensively metabolized (i.e., resulting in excretion o f minimal parent API) 
and that fell near the imputed maximum range would indicate the possibility that disposal 
was a significant contributing source.
Knowledge o f the categories, types, and quantities of drugs being disposed can help 
guide the selection of targets for environmental monitoring and for study o f the potential 
impacts on both the environment and human health (from inadvertent exposure to 
ambient residues from the environment). In this study, the disposed drugs were 
introduced to sewage known to be treated by particular, locally serving WWTPs, making 
possible the calculations o f minimum amounts o f APIs introduced to sewage. The data 
can also be used, in conjunction with requisite demographics data, to derive virtual 
predicted introduction concentrations (PICs) for disposed drugs (concentrations smoothed
I
over time), for the first time allowing an estimation o f the actual or estimated impact of 
drug disposal on total environmental loads o f pharmaceuticals.
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Furthermore, the data may provide valuable insights regarding use, nonuse, and 
misuse of medications, which can then serve healthcare practitioners in their approach to 
treatments prescribed. The coroner data also provide some insight to what categories of 
drugs accumulate due to patient non-compliance, and therefore which drugs have the 
highest potential for accumulating unused, eventually requiring disposal.
Interpretations that could be derived from the data include patient compliance rates 
and abuse rates. Patient compliance and adherence is an important issue in the medical 
community, as it greatly impacts therapeutic outcomes and is a major factor in health care 
cost (Foxhall, 2007; Haynes, 2006). While these terms are often used interchangeably, 
non-adherence is when a patient attempts to follow the directions o f the physician but is 
unable to adhere to all instructions for proper use and consumption. Non-compliance, on 
the other hand, is when a patient, for any number of reasons, willingly chooses to not 
comply with treatment as prescribed by the healthcare practitioner. There remains a 
subtle difference and that difference is often disregarded in the literature. This discussion 
uses the words synonymously since the end-result is very similar.
Compliance is also a major factor leading to the accumulation of drugs in households, 
and therefore, has direct ramifications for the environment (because of consequent 
disposal). The rate o f compliance is frequently discussed in the medical and pharmacy 
communities, and wide ranges of rates (ranging essentially from 0% to 100%) are often 
stated with little supporting data. A report released by the National Community 
Pharmacists Association and Pharmacists for the Protection of Patient Care states that 
38% of consumers questioned had forgotten to take a prescription medication, and 29% 
of those surveyed said that they had at least once stopped taking a drug before the
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prescribed period was over (NCPA, 2006). The same survey found that 74% of 
respondents admitted to non-compliant behaviors including skipping doses, taking less 
than the recommended dose, or forgetting to take medication. In a survey by Abahussain 
et al. (2006), 25.8% of the respondents reported self-discontinuation o f treatment 
regimens. A persisting, unanswered question is the percentage o f accumulated, unwanted 
medications that derives from non-compliant behavior.
Methods
Data as described were collected from the Clark County Coroner's Office (CCCO) in 
Clark County, Nevada. The total available data were selected from the 13-month period 
of January 2005 through January 2006 as this was the most recent accessible data for an 
entire calendar year. In this period, there were 1,632 coroner cases having drugs that were 
inventoried and therefore suitable to evaluate in this study. The most recent census for 
Clark County estimates a population o f 1.7 million people (US Census Bureau, 2006). 
Data were then entered into a spreadsheet, reviewed for accuracy by comparing computer 
records with manual file records, and analyzed.
As indicated on the CCCO website, there were 13,761 deaths reported in Clark 
County in 2005. O f this total, 10,135 deaths were reported to the Clark County Coroner. 
The total number of cases accepted as coroner cases was 3,393. Some of these cases, 
however, were not deaths in the home environment. For example, coroner cases include 
traffic accidents or bodies found outdoors. For obvious reasons, these case files usually 
did not include medication inventories. Certain other cases, while located in a home 
environment, did not have any unused medications to report. Often these cases were
28
deaths of minors or young adults. The 1,632 cases reviewed (48% of the total coroner 
cases) represent those cases that contained a medication inventory log. Fifty-eight o f the 
cases reviewed were from January 2006. To consider the data on the basis of a complete 
calendar year, 1,574 cases therefore contained medication inventory logs during 2005.
The cases reviewed represent approximately 11% of all 2005 deaths reported in Clark 
County. Note that this frequency of occurrence of drug-inventory data may not be 
representative of the frequency at other locales, but would have no influence on data that 
might be collected in other locales.
The 2005 death rate for Nevada is comparable with that on a national basis. In 2005, 
the 13,761 deaths in Clark County’s population o f 1.7 million represented a rate of 0.008. 
In the US, during 2005, there were 2,432,000 deaths in a population of 297.8 million 
(NCHS, 2006), also a rate of 0.008%. This is significant in terms of relating the 
populations and extrapolating the data.
The data compiled by the coroner office in Clark County resides in handwritten 
and/or digital notations recorded by case number. For this study, each case was reviewed 
for data regarding pharmaceuticals located and disposed of. The listing o f the specific 
pharmaceutical information (such as name of drug, prescription dosage, prescription date, 
and directions for use) is originally recorded on a written inventory sheet included in each 
case file; a facsimile example is shown in Figure 2. The information is then entered as a 
narrative parameter within the coroner database. However, not all cases had been entered 
into the case database, often due to time constraints of entering multiple medications 
found in a particular case. Therefore, each case, including its inventory sheet and digital
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file, was evaluated manually in order to compile all pharmaceuticals disposed during the 
research period. Each paper file was reviewed for accuracy and thoroughness.
This information was recorded in an Excel spreadsheet, and masses o f APIs disposed 
of were calculated using the number of doses identified and the dosage strengths 
reported. The information was alphabetized by API name as well as sorted by 
pharmaceutical category as listed in the Tarascon Pharmacopoeia (Tarascon, 2007).
It is important to note that sometimes the brand name was listed in the coroner 
records as opposed to the generic name. For example, furosemide, an oft-prescribed 
diuretic, was frequently listed as Lasix®. The data were scoured for these inconsistencies, 
and all brand names were replaced with generic names for proper chemical distinction. In 
addition, combination drugs, which are developed and prescribed with increasing 
regularity, were separated into their component APIs. For example, Lottab® was entered 
into the spreadsheet as both hydrocodone and acetaminophen, with appropriate dose 
amounts applied.
Results '
The 13-month CCCO dataset contained greater than 5,000 discrete entries, 
representing on average a little over three APIs per decedent. Each entry represented a 
single API from a medication identified at the scene. A medication is most often 
identified by the label on the prescription bottle. In some cases, no pills were remaining
i
from a prescription, and the entry then showed zero doses disposed. As described above, 
those medications that were dispensed as combinations of APIs were separated in the 
spreadsheet into their components. Therefore, one entry does not necessarily correlate
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with just one medication inventoried. Some representative data are presented here for 
illustrative purposes.
The most prevalent method of disposal for the CCCO was to flush the inventoried 
medications into the sewage system. Greater than 92% of the medications found at 
decedent sites were flushed. Approximately 7% of the medications were disposed o f in 
the household trash o f the home o f the decedent. Less than 1% was incinerated by law 
enforcement service. This latter disposal route usually occurred when loose, unidentified 
pills were found. These pills would be collected and transported to the offices o f the 
Coroner and subsequently identified by Las Vegas Poison Control and inventoried. 
Following this, the Coroner would apply for a court order to dispose of the drugs, since 
the act o f taking them into possession then made these drugs evidence. The court order 
would allow cremation o f the drugs in the possession of the Coroner.
During the 13-month period of this pilot study, at least 325,000 doses of a wide array 
of drugs were disposed of into the sewage system by the CCCO; in Clark County, this 
system is serviced by three tertiary treatment plants. This estimate does not include the 
multitude of other medication formulations (such as powders and liquids) and delivery 
systems (such as inhalers, patches, and syringes). Powders and liquids were also disposed 
of into the toilet but were not quantified in this study. Inhalers, patches, and syringes 
were disposed in the household trash and were not quantified in this study. The 325,000 
doses (1 dose = 1 pill/tablet/capsule) represent greater than 102,000,000 milligrams of 
APIs disposed of into the sewage system over the 13-month period. These 102 kg are 
specific to the route o f toilet disposal. Recognizing the assumption regarding the 
similarities in death rates between Nevada and the country, it is not unreasonable to
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extrapolate these data to obtain an estimate of at least 17.9 billion milligrams (17.9 metric 
tons) of APIs disposed of annually into the national sewage systems by the deceased 
population alone (mass disposed by CCCO multiplied by the ratio of the US population 
to the Clark County population).
The following two examples illustrate the utility of the coroner dataset. First is an 
API that serves as a contaminant archetype because of its frequency of occurrence in 
environmental monitoring studies -  the anticonvulsant, carbamazepine (CBZ). The 
second comprises the beta-blocker cardiac medications. Analogous data exist in the 
dataset for 200 other APIs.
The anticonvulsant CBZ is considered the primary drug for partial and tonic-clonic 
seizures and is also used in other treatments. While a low percentage (1-3%) of CBZ is 
excreted unchanged, another portion is excreted as conjugates, which can be hydrolyzed 
back to the parent CBZ, once released to sewage (Bendz et al., 2005). Therefore, the 
effluent concentrations often may not be much reduced from influent concentrations. The 
efficiency of CBZ transformation in WWTPs and in the environment is not high, leading 
to widespread persistence of measurable ambient, environmental residues (Bendz et al., 
2005).
During the 13-month period o f the collected data, there were 1,755 tablets of CBZ 
identified and disposed o f in the homes of the decedents. These tablets represented 
307,300 milligrams (307 g) o f pharmaceutically active CBZ introduced directly into the 
Clark County sewage system. Since the most common dose prescribed was 200 mg, it 
would take roughly between 51,000 and 154,000 oral doses of CBZ for excretion to 
contribute the equivalent of 1,755 tablets of the pharmaceutically active CBZ disposed of
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by the CCCO (assuming an excretion rate ranging from 1 to 3%). The Clark County 
sewage system has average sewage flows o f 144.4x10^ gal/day (MGD) (LVWCC, 2007). 
Assuming a hypothetical, uniform and consistent daily disposal to sewage, a minimum 
averaged concentration of 1.4 ppt CBZ (see Equation 1) could be expected in the influent, 
as well as possibly the effluent, from the disposal o f CBZ by the CCCO alone.
Equation 1:
(307 g/13 months) x (12 months/year) x (1 year/365 days) x (1 day/144x10^ gal) x (1 
gal/3.7854 L) = 0.0014x10'^ g/L = 1.4 ng/L = 1.4 ppt CBZ in WWTP influent
It is important to note that in reality the disposal of medications does not take place at 
a uniform, constant rate, but rather episodically. This will result in plug-flows that have 
higher transient concentrations; this is one of the variables involved with fluctuating 
levels in sewage (Daughton, 2007).
Assuming CCCO serves the entire Las Vegas basin, this population is served by the 
Clark County Sewage District. The US Census Bureau estimates 1.2 million adults over 
the age of 18 in Clark County in 2005 (US Census Bureau 2007). However, more 
specifically, and perhaps more accurately since not only are most prescriptions written 
for older adults (a result of a greater incidence of polypharmacy), there are approximately 
183,000 people in Clark County over the age of 65 (US Census Bureau, 2007). The 
CCCO data derive from 1,632 cases (over the course of 13 months) and represent 
approximately 0.0089% of this sub-population. This estimate can be used roughly to 
correct the estim ate o f  1.4 ppt (in STP influent) to 157 ppt CBZ disposed  by  the 
proportion of the sub-population aged 65 or older in Clark County.
The 1,632 cases represent approximately 307 g of CBZ identified and disposed 
annually. This is roughly 0.19 g o f CBZ per case. As explained above, these deaths
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represent 11% of all deaths reported in Clark County in 2005. Assuming similar coroner 
statistics across all 50 states, 11% of all deaths in the country would be 267,500 yielding 
a potential 50.8 kg of CBZ being disposed nationwide on an annual basis just by coroner 
offices.
For the second example, consider the |3-adrenergic blockers, commonly referred to as 
bcta-blockers, which are used in the treatment of hypertension, systemic, and ophthalmic 
disorders. The compiled CCCO data set indicates almost 10,000 leftover beta-blocker 
pills that were disposed of, translating into almost 900,000 milligrams (900 g) of beta- 
adrenergic antagonist APIs disposed into sewage.
By using the prescription date listed in the coroner records, dose-frequency 
instructions, doses remaining, and the date of death, compliance or noncompliance can be 
ascertained. The data for beta-blockers represented an approximate 33% rate of 
noncompliance among the decedents for all the medications listed in the inventory. Of 
great clinical interest, in almost 70% of those noncompliant cases, the cause o f death 
listed by the medical examiner was the precise disease the unused drugs were intended to 
treat. By contrast, the cause of death listed due to acute toxicity of prescribed drugs, 
which by definition does not include illicit drugs, was listed in 7% of the cases.
The study decedents possessed an average of seven prescriptions. These medications 
were the same pharmaceuticals that are commonly prescribed in the general population 
(RxList, 2007) and were not present in inordinate quantities. While one might expect that
I
those near the end of life would be taking larger quantities of particular pharmaceuticals, 
for example, opiates for pain, this did not appear in the CCCO data. The number of 
hydrocodone prescriptions for this data set was 692 (which may be due to high
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compliance). This did not necessarily represent one prescription per case since often 
more than one hydrocodone prescription was listed for a single decedent. While details 
regarding the number of specific pharmaceutical prescriptions per decedent will be 
elucidated in future articles, this basic information can be used to assess the 
comparability o f local, state, and national prescribing and dispensing practices. There 
were an estimated 1.8 million hydrocodone prescriptions in Nevada during 2005 
(Haynes, 2005), a state with almost 2.5 million people (US Census Bureau, 2007). In the 
same year, there were greater than lOI million hydrocodone prescriptions written in the 
US (RxList, 2007), a country of almost 300 million people (US Census Bureau, 2006). 
While the ratios of prescriptions to population count in Clark County (42%) and Nevada 
(72%) are higher than national figures (33%), they most likely represent the upper range, 
and may be due to local practices and demographics. This information is valuable 
because it serves to establish the relevance and representativeness of the data with regard 
to its overall representation of the US population. In addition, it may be easier to address, 
and alter, prescription and dispensing practices on a local basis. Comparing local 
prescription behaviors with similar localities and communities may provide information 
and recommendations for more efficient, effective, and prudent prescription handling.
Discussion
The data collected from the records of coroner offices regarding the quantities and 
disposal of unused drugs can be used as a comprehensive and accurate data set from 
which to derive a wealth o f information regarding the extent of environmental disposal of 
pharmaceuticals that span all therapeutic classes; some example applications for these
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data are summarized in Table 1. The data can provide insights to answer questions such 
as, in what quantities are specific medications disposed of, and what categories of 
medication are commonly found in the coroner offices inventories. The coroner inventory 
is useful because it includes data on specific drugs with dosage information that were left 
over following a death, and that are directly disposed into the sewage systems by the 
coroner staff. The disposed dosage amounts could prove very valuable in better 
understanding the sources and their relative contributions of drug residues as measured in 
STP influents or effluents. As additional water monitoring studies are conducted, this 
information could be helpful in correlating water concentrations and usage patterns 
among local populations.
The same dataset provides insight into noneompliant behaviors among the population 
ineluding the abuse and misuse of prescribed medications and prescription trends o f the 
representative géographie area. Combined with the information on disposal, these factors 
need further evaluation for various scenarios that would have an effect on ambient 
environmental concentration levels, as well as indicating the efficiency of prescribing and 
patient education by medical care providers.
Further analysis can reveal those medications that accumulate at rates 
disproportionate to their dispensed frequencies and those that accumulate at the highest 
absolute rates and in the highest quantities. Data such as these would be useful, for 
example, in indicating which drugs experience high non-compliance or are prescribed in 
excessive quantities. With these data as a guide, it is possible to target these drugs.for 
emphasizing better prescribing (or dispensing) practices, as well as more prudent disposal 
practices. An additional use for this inventoried data would be to identify those drugs that
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have not been the target of monitoring efforts, but yet exist in the coroner data at 
significantly high rates. For example, greater than 80,000 milligrams of lisinopril, an 
angiotensin-converting enzyme (ACE) inhibitor, was disposed of. The ACE inhibitors 
have never been routinely targeted in monitoring studies.
There are two major approaches for ameliorating the disposal issue -  source control 
and pollution prevention. The first would focus on an effective and environmentally 
friendly way to dispose o f pharmaceuticals that go unused. The second reduces the size 
of the source by reducing the quantities o f medications that accumulate and which would 
have then required disposal. The supply and distribution of medications coupled with the 
behavior patterns o f patients and physicians dictate the amounts o f pharmaceuticals 
having the potential to accumulate. Patient noncompliance to treatment regimens and 
physician prescription patterns could be addressed to better optimize patient care and 
reduce accumulations. These approaches may help to limit the accumulation of 
pharmaceuticals and reduce the ready source of those drugs that are highly addictive and 
which are abused, misused, or targets o f diversion.
Minimizing the need for drug disposal will need to bring together professionals from 
the health care and insurance industries, government, environmental sciences and policy, 
and engineering. The research described here, and to be delineated in upcoming 
publications, begins to address some of the long-standing uncertainties in science that 
will need to be resolved. It also exposes other areas of a complex web of pharmaceutical 
sources that are in need o f individual disposal strategies, and potential ways in which the 
amounts of accumulated drugs can be reduced. In addition, the research introduces a 
source of data that has previously been overlooked -  where a potentially large source of
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drags introduced into the environment is already being inventoried and cataloged. This 
information is valuable for furthering discussions regarding human medication behavior 
and also provides a basis for future research into determining what quantities of APIs are 
disposed, and which then serve as a source o f APIs that can enter the environment.
A project creating a unified network of inventoried-drag databases from coroner 
offices around the country could prove highly useful. Such an effort could first compile 
existing coroner data, and then automate for future collection. These data could be used 
to improve patient outcomes and reduce costs of health care. In turn, improved 
prescribing practices should automatically reduce the quantities o f medications needing 
disposal. The purpose of this work is to provide some examples of the types of inferences 
and deductions that can be derived from coroner data. An overarching objective is to 
catalyze consideration for adoption o f a more comprehensive version of this approach on 
regional or national scales.
Note Added: Soon after the conclusion of the project reported here, the Clark County 
Coroner Office began discussions with local hazardous waste transporters regarding the 
feasibility of removal and transport o f their collected leftover decedeht drags to 
incinerator facilities. The intent is to cease disposal of the pharmaceuticals into sewage. 
These discussions were partly a result of the information provided by this research 
project, as well as the desire of local water authorities to comply with the newly issued 
federal guidelines. The CCCO hopes to develop a model for proper and safe disposal of 
pharmaceuticals acquired by the coroner. ,
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Coroner drug inventories can be used to:
Determine
• Types and relative amounts of APIs disposed
• Actual quantities of APIs disposed
• Fraction of APIs disposed by various routes (e.g.,
sewage vs. trash)
• Minimum limits on amounts of individual APIs
disposed
• Putative maximum limits on amounts o f individual
APIs disposed
• Predicted concentrations introduced to STPs
• Relative significance o f disposal with respect to the
overall environmental occurrence o f an individual 
API
• Those APIs for which disposal is insignificant with
respect to their overall environmental occurrence
• Those APIs for which disposal might play a significant
role in their overall environmental occurrence
• Those medications for which patient compliance rates
are low
Guide
Selection of APIs for targeted monitoring in sewage 
streams and the environment in specific geographic 
locales
Recognition o f APIs that are being over-prescribed 
Recognition of medications with poor patient 
compliance
Table 1: Potential A pplications for Coroner Drug Inventories
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BEYOND THE MEDICINE CABINET: AN ANALYSIS 
OF WHERE AND WHY MEDICATIONS 
ACCUMULATE
Overview
Active pharmaceutical ingredients (APIs) from medications can enter the 
environment as trace contaminants, at individual concentrations generally below a part 
per billion (pg/L) (Daughton, 2002). APIs enter the environment primarily via the 
discharge of raw and treated sewage. Residues o f unmetabolized APIs from parenteral 
and enteral drugs are excreted in feces and urine, and topically applied medications are 
washed from skin during bathing. These trace residues may pose risks for aquatic life and 
cause concern with regard to subsequent human exposure (Daughton, 2008).
APIs also enter the environment from the disposal of unwanted medications directly 
to sewers and trash (Bound and Voulvoulis, 2005). The relative significance of this route 
compared with excretion and bathing is poorly understood and has been subject to much 
speculation. Two major aspects of uncertainty exist: the percentage o f any particular API 
in the environment originating from disposal is unknown, and disposal undoubtedly 
occurs from a variety o f dispersed sources. Sources of disposal, along with the types and
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quantities o f APIs resulting from each source, are important to understand so that 
effective pollution prevention approaches can be designed and implemented.
Aeeumulation of leftover, unwanted drugs poses three major concerns: (i) APIs 
disposed to sewage or trash eompose a diverse souree of potential chemical stressors in 
the environment, (ii) Accumulated drugs represent increased potential for drug diversion, 
with its attendant risks of unintentional poisonings and abuse, (iii) Leftover drugs 
represent wasted healthcare resources and lost opportunities for medical treatment.
The work presented here has four major purposes: (I) Define the processes, actions, 
and behaviors that control and drive the consumption, accumulation, and need for 
disposal of pharmaceuticals. (2) Provide an overview of the diverse locations where 
pharmaeeutieals are used and aecumulate. (3) Present a summary of the first cataloging of 
APIs disposed by a defined subpopulation. (4) Identify opportunities fOr pollution 
prevention and source reduction. Note: This chapter has been previously published as 
Ruhoy and Daughton 2008.
Introduction
Pharmaceuticals uses, for both humans and animals, inelude therapy, disease 
prevention, diagnosis, eosmeties, and lifestyle. Residues from hundreds of widely used 
aetive pharmaceutical ingredients (APIs) ean gain entry to the environment via a complex 
network of sources and pathways, interspersed through numerous parts of society. These
I
potential eontaminants make their way into the environment primarily as a result o f their 
intended use -  as caused by exeretion or bathing. Disposal of unwanted, leftover 
medications to sewage and trash is another source o f entry, but its relative signifieanee is
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unknown with respect to the overall concentrations of APIs in the environment. Wildlife 
and humans can then experience long-term or intermittent exposure to APIs as trace 
pollutants, primarily via contaminated water and foods.
O f the research accomplished to date regarding sources, fate and transport, exposure, 
biological effects, waste treatment, and pollution prevention, very little has been directed 
at the role played by the APIs in the environment originating from disposal of leftover 
medications compared with APIs introduced into the environment through excretion and 
bathing. Leftover, unwanted pharmaceuticals (both human and veterinary) tend to 
accumulate after being set aside, stored, or forgotten —  and this occurs at just about any 
location where people live, work, or visit. Accumulated or stockpiled leftover 
medications are eventually disposed either through formal collection programs (with 
disposal generally at hazardous waste landfills or by incineration) or simply by the end- 
user discarding directly into sewerage or trash. During storage and imprudent disposal 
(e.g., leaving leftover drugs visible and accessible to others), a leftover drug can be 
inadvertently diverted to those for whom the medication was never intended. This can 
lead to poisoning of humans and pets, or can further abuse and addiction. Well-designed, 
efficient disposal programs hold the potential for preventing unnecessary human (and 
animal) exposure and poisonings, as well as for reducing environmental pollution.
Many factors cause medications to remain unused, creating leftover drugs that can 
accumulate. A wide spectrum of forces underlies the generation of leftover drugs, ranging 
from inefficiencies and certain practices of manufacturers, distributors, prescribers, 
dispensers, and patients themselves. Although design of environmentally prudent and 
safe disposal programs is currently being pursued (Reid, 2007), much o f the need for
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drug disposal could be eliminated by focusing corrective actions on these major causes of 
accumulation with the design and implementation of pollution prevention measures. Such 
practices would be part o f a larger program that oversees all the aspects o f unintended, 
adverse consequences of medications. Such a program has been termed 
pharmEcovigilance (Daughton and Ruhoy, 2008).
Leftover medications pose an aeute exposure hazard for both humans and the 
environment. Opportunities are lost for optimal delivery of healthcare, and valuable 
healthcare resources are squandered. The likelihood also greatly increases for drug 
diversion and environmentally unsound disposal. These latter two liabilities can pose 
acute and chronic poisoning risks for humans and wildlife alike (Daughton, 2007).
This research focuses on two major aspeets of the larger topic of pharmaceuticals as 
environmental pollutants: (i) the processes, actions, activities, events, and behaviors that 
cause drug wastage (leading to accumulation and disposal), and (ii) the many and diverse 
physical sources from which stored and accumulated drugs can enter the environment as 
a result of disposal. Such information should prove useful for the design of pollution 
prevention measures that encompass a significant portion of the life cycle of medieations. 
Presented here is the first comprehensive examination of the reasons that medications 
accumulate and the many potential sources or locations from where leftover drugs are 
disposed. Better understanding of the many and varied origins and sources o f leftover 
drugs will allow for the design of pollution prevention actions best tailored to minimize 
or eliminate these accumulations, and therefore eliminate or reduce the need for disposal.
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Background
The use o f human and veterinary pharmaceuticals for their intended purposes is 
accompanied by a very complex network o f routes by which APIs eventually gain entry 
to the environment or result in unintended direct exposures to humans and wildlife (see 
Daughton, 2008, Figure 1; 2007, Figure 1). A holistic, integrated view o f the life-cycle of 
pharmaceuticals includes not just the intended uses o f drugs, but also their unintended 
consequences. A broad spectrum of unanswered questions surrounds the environmental 
lifecycles of drugs (Daughton, 2004). The accumulation and disposal o f leftover drugs is 
but one o f their routes to the environment. In contrast to excretion, however, this route of 
release is more amenable to moderation by environmental stewardship programs, 
especially those designed around pollution prevention (Daughton, 2002, 2003a, b). To 
design and gauge the success o f such pollution prevention programs, the origins and 
sources o f drug release need to be defined, and the absolute or relative contributions of 
these sources to the overall loadings o f APIs in the environment need to be known. The 
individual percentages probably vary dramatically among APIs and among the types of 
packaging (for example, unit-packaged pills are probably not frequently disposed via 
toilets, whereas liquids are probably routinely poured down drains). In particular, 
disposal could prove to be a significant source for those APIs that would otherwise have 
been extensively metabolized.
O f the major sourees and routes by whieh drugs gain entry to the environment, the 
types and quantities of APIs introduced to sewage as an unintentional result of their 
intended use (primarily as a result of excretion and bathing) are amenable to estimation 
using modeling based on usage data combined with parameters such as pharmacokinetics
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(portion of parent API excreted unchanged) and known efficiencies of removal from 
sewage treatment; such an approach has been used by Kostich and Lazorchak (2007). In 
contrast, gaining an understanding of the types and quantities of APIs introduced directly 
and purposefully to the environment by the disposal of unwanted, leftover drugs has been 
more problematic because o f a dearth o f comprehensive or reliable data. O f the total 
loadings o f a particular API in the environment, it is unknown what fraction results from 
drug disposal. Chapter 2 presented a novel methodology for obtaining comprehensive and 
accurate drug disposal data at the community level by the use o f existing drug inventories 
collected during coroner investigations. These unique data can then be used for a variety 
of purposes (see also Ruhoy and Daughton, 2007).
Another important aspect o f drug disposal, and one that is elucidated further in this 
chapter, is the location at which leftover, unwanted medications accurfiulate. Probably 
more than for any other perishable, non-food item consumed by humans, medications are 
used and stored at a vast array of locations throughout society, including schools and 
nurseries, hospitals, nursing homes, hospice care centers, emergency shelters, 
humanitarian organization locations, doctor and dentist offices, public-use first aid kits, 
veterinarian offices, farms, military bases, and prisons, among others. These products are 
frequently prescribed, dispensed, or purchased in excess or are not fully consumed as 
directed (e.g., as a result of poor compliance among patients), leading to the 
accumulation of unwanted, leftover drugs. A variety of other factors also promote drug
i
wastage; bulk packaging of certain OTC drugs in quantities that cannot be consumed 
before expiry is one example. These factors have been categorized by Daughton and 
Ruhoy (2008).
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Unused pharmaceuticals pose unknown risks for the environment and take a toll on 
human health. Based on data obtained in 1999 from a series of retirement communities, 
Morgan (2001) roughly estimated that the annual value of wasted medications just for 
adults older than 65 years in the US could exceed $1B; this represented 2.3% of total 
medication costs. The accumulation of non-utilized pharmaceuticals designed to treat 
human maladies as well as to treat and care for both domestic and farm-reared animals is 
emblematic of a society-wide problem that affects both human and ecological health. It is 
also one whose prevention could lead to immediate benefits for both.
The existence and extent o f unused pharmaceuticals could be adopted as a direct 
measure of non-compliance and poor adherence by the patient population. Non- 
compliance is often a significant factor in reducing the physician’s ability to treat and can 
lead to poor therapeutic outcomes. The collective volumes of excess and unused 
medication can lead to unintentional pharmaceutical poisonings of children (resulting in 
morbidity and mortality), facilitate abusive use, and promote emerging social problems 
such as teenage "pharming" (the theft and communal sharing and abuse of 
pharmaceuticals by teenagers) (SAMHSA, 2007). In addition, the subsequent imprudent 
disposal of unwanted drugs via domestic trash (e.g., in unsecured containers) encourages 
and facilitates their reclamation by others (especially addicts) for non-medical purposes.
A better understanding of medication usage could lead to the design of processes that 
could reduce or eliminate the very need for drug disposal. Two aspects must be 
considered; (I) the factors that lead to the generation of leftover, unwanted medications, 
causing them to accumulate unused, eventually becoming wastes, and (2) the many and 
varied locations and sites in society where medications accumulate (the relative
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significance of each source of accumulation is currently not known). The first step is to 
catalog the sources and assess why drugs accumulate at these locations.
A major question is whether implementing any number of pollution prevention or 
stewardship measures could control the disposal of drugs. What causes or drives the need 
for disposal, and can the incidence or magnitude o f disposal be better understood and 
reduced or eliminated?
Note that the current approach to preventing pollution from drug disposal is to 
implement various means for collecting leftover drugs and disposing of them in the most 
prudent manner available (primarily as hazardous waste) (Glassmeyer et al., 2008). For 
those countries (e.g., Australia, Canada, France, New Zealand, Sweden, UK) having 
formal collection programs for unwanted drugs (those no longer in the commercial 
distribution/sales system), the most common approach is for consumers to return their 
medications to local pharmacies; for collection practices in the US, see discussion of 
Glassmeyer et al (2008) and examples cited by IISG (2007). These “down-stream” 
approaches are generically termed consumer "take-back" or "return" programs. In the US, 
the design of take-back programs is much more complicated, as medications cannot be 
returned to operational pharmacies (unless a formal FDA recall has been issued); several 
federal regulations currently make any type of universal collection program extremely 
complex and inefficient (see background presented in Daughton, 2007). This, coupled 
with the growing imperative in the US to prevent drug diversion, prompted the White 
House Office of National Drug Control Policy (ONDCP, in conference with the FDA and 
EPA) to implement guidanee for consumers for disposing o f drugs in a manner that
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reduces entry o f APIs to the environment while also protecting public (and animal) health 
by minimizing diversion and accidental exposure (Daughton, 2007).
Regardless o f whether efficient collection programs can be developed for public use, 
none will ever capture all medications that accumulate as wastes; no type o f disposal 
process (whether landfilling as hazardous waste, incineration, or other type of complete 
destruction) is free of the potential to generate hazardous by-products or release 
pollutants in the future; and all have energy costs for transportation, storage, or 
destruction. Instead, the optimal approach could be to prevent the need for disposal in the 
first place -  an “up-stream” approach that maximally protects the environment and at the 
same time has the potential to improve health-care outeomes, reduce healthcare eosts, and 
lessen the ineidence o f morbidity and mortality caused by human (and animal) exposure 
to unsecured, unwanted drugs.
Numerous factors play roles in the accumulation o f drugs by end-users, whether they 
are healthcare professionals, physicians, patients themselves, veterinarians, farmers, or 
humanitarian relief workers. Some o f these factors are expiry, patient non-compliance, 
and over-prescribing or excessive purchase; these have been summarized by Daughton 
and Ruhoy (2008). Patients will discontinue taking medication due to, among other 
reasons, intolerable or adverse effects, inconvenience in dosing schedule, a change in 
therapy as prescribed by their physieian, forgetfulness, or even a poor pereeption o f the 
severity of their illness. Expiration is an oft-cited reason for accumulated drugs; however, 
other numerous factors play a significant role (Pound et al., 2005). Poor adherence and 
non-eompliance continues to be a major source of public health concern (DHHS, 1990). 
Significantly, the numbers of consumers who do not follow medication regimens in the
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u s  continue to be substantial, and addressing the causes could improve outcomes and 
reduce morbidity and mortality (Bosworth et al., 2006; O ’Donohue and Levensky, 2006).
Sites o f drug accumulation extend far beyond the household medicine cabinet. Some 
drugs are simply forgotten by consumers at a distant location (i.e., hotels, workplace, and 
hospitals) and some are intentionally abandoned. Physician and dentist offices have 
supplies of drugs on hand for intra-office procedures and sample dispensation. However, 
some areas of substantial drug wastage are independent of the individual consumer as a 
patient. These locations are associated with the demands and expectations o f the public 
for the easy accessibility and availability of medications. Public buildings, vacation areas 
and marine vessels, and societal institutions such as prison systems and military bases are 
all locations where drugs are stored in significant quantities in case the need arises. This 
prophylactic approach increases the probability o f eventual expiration or simply non-use 
o f the medications, thus necessitating their disposal.
The effort to address unused pharmaceuticals must examine all aspects o f licit drug 
use and non-use. While consumer non-compliance is a significant factor, a strategy to 
combat pharmaceutical waste should include preventative measures that encompass all 
facets o f drug accumulation and waste.
An overview of the diverse spectrum of locations where drug buildup and eventual 
disposal could occur is presented in Figure 3. It begins with the actual production of the 
pharmaceutical and traces the many places a drug may end up in following its purchase,
I
whether by prescription, over-the-counter, or by other means such as the gray market. 
Each rectangular box shown in three dimensions in the flow chart represents a particular 
site where accumulated human and animal medications might be found.
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For each location represented, diseussion is presented on where drugs ean reside, 
possible causes for their accumulation at each particular site (e.g., expiry, over- 
preseribing, ete.), the method by whieh they aeeumulate (e.g., abandoned, orphaned, 
stockpiled), and the problems posed by their aeeumulation (e.g., diversion, disposal, ete.).
Leftover drugs ean indieate medieal therapy was never eompleted, the medication 
was the ineorreet choiee of treatment, or that healtheare resources have been wasted. The 
aeeumulation of these leftover drugs ean further lead to or promote diversion to others, 
resulting in drug abuse or purposeful human poisonings, or aeeidental poisonings in 
humans (espeeially ehildren and the elderly) or pets beeause of unseeured stoekpiling. 
Eventual disposal of the aeeumulated drugs may maximize the introduetion of APIs to 
the environment by eireumventing natural physiologieal proeesses that ordinarily might 
have reduced their amounts via exeretion. Disposal may also result in aeute wildlife 
poisonings (Daughton, 2007).
Diseussion
The origin of all pharmaeeutieals is probably the simplest part of the puzzle. 
Pharmaeeutieals are manufaetured and produeed within faeilities owned or eontracted by 
the individual pharmaeeutieal eompany. Following their manufaeture and produetion, the 
drugs are transported to those entities that are then eharged with distribution of the drugs. 
These entities inelude both traditional briek-and-mortar pharmaeies and online e- 
eommeree pharmaeies (some of whieh operate illegally as “rogue” pharmaeies), and 
distribution eompanies (often a subsidiary o f the pharmaeeutieal eompany itself);
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distribution companies stock other locations that may manage their own internal 
pharmacies, whieh may themselves become points o f aeeumulation.
Currently, database and inventory technology allows for very efficient manufaeture 
and distribution. Manufacturing companies are able to accurately estimate demand and 
potential orders from their various customer retailers and wholesalers (Smith, 2007). This 
allows them to produce exactly what is needed, when it is needed, and therefore produce 
very little, if  any, unused and unwanted medieations that ean accumulate. For a 
diseussion on waste generation during the medication produetion process itself, whieh is 
not a topic of this discussion, see Velagaleti and Bums (2007).
The following discussion describes and evaluates: (1) the factors that lead to the 
generation of leftover, unwanted medications and (2) the many and varied locations and 
sites in society where medications accumulate and from where they are subject to 
disposal.
Actions designed to control the many factors that lead to dmg wastage and 
accumulation clearly could help in reducing the types and quantities of APIs that are 
eventually introduced to the environment by way of disposal. Note that while these 
factors can also play roles in increasing the unintended release of APIs to the 
environment via excretion (improving patient compliance is one example), a wide 
spectram of other factors contribute more to the over-usage o f dmgs, resulting in the 
unnecessarily higher excretion rates o f APIs. Many of these factors have been 
summarized by Daughton (2003 a, b); two examples inelude the manufacture of raeemic 
drags (where only one optical isomer is the therapeutic entity) and the use of 
unnecessarily high doses and durations o f treatment (which often are established
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expressly for clinical trials in order to maximize the chances o f favorable outcomes but 
which are never reevaluated or adjusted downward once the drug reaches final approval). 
In fact, downward-adjustment of doses by the patient (self-regulation) is a major factor in 
“non-compliance,” and is caused by patients’ concerns regarding the medications 
themselves (Pound et al., 2005).
Figure 4 demonstrates the many factors that influence drug usage - - and therefore 
pharmaceutical wastage and accumulation. Identifying and assessing these parameters is 
an important first step in recognizing the points where pollution prevention efforts could 
be designed and implemented.
Factors Leading to the Generation of Leftover, Unwanted Medication
Prom otional
York University (2008) researchers estimate the US pharmaceutical industry spends 
almost twice as much on promotion as it does on research and development. Promotional 
items and programs put forth by both pharmaceutical sales representatives (“sales reps”) 
and manufacturers and distributors target both the general population or specific sub­
populations and carry a positive message with regard to the use and benefits of 
consuming prescribed pharmaceuticals. Manufacturers, distributors, and sales reps use 
various approaches for prom otional to induce, entice, or convince physicians and other 
healthcare professionals of the effectiveness and the appropriateness o f prescribing their 
drug to a particular patient population. These prom otional can be in the form of 
advertising in medical journals, continuing medical education (CME) credits in exchange 
for participation in a marketing program, and hosting various conferences, meetings, and
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workshops. Furthermore, an aggressive campaign o f “sampling” (providing sample 
packages of the medication at no cost to the physician) and “detailing” new, as well as 
older, products can influence the extent to which a healthcare professional will consider a 
drug product in treating a particular patient and/or disease.
Consumers and physicians both report that prescription drug advertisements are 
increasingly influential. Surveys o f patients and physicians have concluded that patients 
have asked their doctor about a medication solely as a result of direct-to-consumer (DTC) 
marketing, and physicians then consider prescribing such medications as a result of the 
patient’s request (Rosenthal, 2003). It is probable that DTC advertising brings more 
patients into a doctor’s office seeking a prescription for a particular drug (Donohue and 
Bemdt, 2004).
Concerns regarding conflicts of interest - - for example, a particular manufacturer 
hosting a CME course (which physicians and other professional are required to obtain on 
a yearly basis in order for their practicing license to remain in effect) - - have been 
discussed by various law and health groups but no consensus course of action has been 
reached. If these promotionals were limited and regulated, there would be much less 
direct interaction and correspondence between those that produce and sell the drug and 
those who can alter its rate of prescription and, hence, consumption. Indeed, the recently 
reauthorized Prescription Drug User Fee Act (PDUFA) provides greater authorization 
and resources for the FDA to evaluate and assess the safety of new medications as well as
i
public advertising (US FDA, 2007). Furthermore, several academic rhedical centers 
across the country are instituting policies o f their own with regard to the relationships 
between doctors and relevant industries. For example, the University of Pittsburgh
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School O f Medicine has established a program that provides for the prohibition o f gifts 
and free lunches, addresses faculty speaking and consulting involvements, and disallows 
the presence of pharmaceutical representatives from patient areas 
(http://www.coi.pitt.edu/IndustryRelationships/index.htm) (also see: Tregaskis, 2008).
Counteracting Promotions
Counter-promotion involves programs and interventions to teach health professionals 
or students to critically assess drug promotion, i.e., to teach health professionals how to 
interact with sales representatives and interpret promotional information. Norris et al. 
(2005) describes programs that are intended to question the claims made by drug 
manufacturers in advertisements and educational materials directed at both patients and 
physicians. The effect o f these counter-promotional activities is still unknown for they 
are still far outnumbered by the promotional programs. In the US, the American Medical 
Association has guidelines about gifts from the pharmaceutical industry incorporated in 
its Code of Ethics (http://www.ama-assn.org/ama/pub/category/5689.html). These 
suggest that gifts to doctors should primarily benefit patients and should not be of 
substantial value. Further guidelines for regulating interactions between healthcare 
practitioners and student doctors are needed to establish positive and beneficial 
relationship with regard to the proper use and prescribing o f medications.
Prescribing
Prescribing medications to treat disease is not a simple and straightforward procedure. 
There are many factors and considerations, not all of which are justified by the literature 
(especially by evidence obtained from double-blind randomized controlled trials), that 
influence decisions to prescribe and what to prescribe.
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As already discussed, DTC advertising has a direct effect on the knowledge base, and 
therefore the perspeetive and desires, of a patient. A doetor may be persuaded to eonsider 
a speeifie medication in the face of an ardent patient. In addition, if  a physician were to 
disagree with a patient’s request and preseribe an alternative medieation, this may affeet 
the adherenee of the patient to the medieation, as well as adversely affect the relationship 
between physieian and patient (Pound et al., 2005; van Dulmen et al., 2008).
Direet-to-physieian marketing may play a role as well. Pharmaeeutieal manufaeturers 
not only advertise to physicians via conventional methods (i.e., medical journals), but 
also dispatch representatives of the eompany to regularly visit and educate physicians, 
physicians-in-training, and office staff on their products -  both old and new. These visits 
(referred to as “detailing”) often inelude boxes of free samples (referred to as 
“sampling”) of the pharmaeeutieal produet as well as meals and marketing trinkets sueh 
as pens, elipboards, and eups. Human nature as it is, it is easy to believe this 
eommunieation style may play a role in the physieians awareness and knowledge of 
medieations to be used to treat a partieular ailment. Manehanda et al. (2005) outlined the 
various researeh on physieian and patient learning about drugs.
Optimal prescribing behaviors are complicated and time-eonsuming. While much of 
medicine is practiced using algorithms and protoeols, often there is not one perfect 
method of treating a chronie ailment, and eaeh patient needs to be regularly monitored 
and managed. Genetic medicine (sometimes ealled “effieacy pharmaeogeneties”) is 
teaehing us that each individual may have a different response to treatment as well as a 
different eourse of disease. Drugs ean have many polymorphie meehanisms and result in 
various physiologieal efleets and changes in different individuals (Foxhall, 2008). Yet
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treatment is often arrived at based on the conventional generic methods of treatment of a 
disease as well as experience of the physician with beneficial responses in other patients. 
Regardless, without careful adherence to evidence-based medicine coupled with 
individualized therapy and treatment, there is the potential for increased misuse, 
mismanagement, and non-compliance with the medication.
Dispensing
Dispensing practices can affect medication usage. Dispensing refers to the method 
and form by which a prescription is filled for a patient. Many pharmaceuticals are offered 
in multiple forms -  pill (which may be swallowable, chewable, or sublingual), liquid, 
intramuscular injection, spray (which may also be used intraorally or intranasally), 
creams or gels (dermally or intravaginally), suppositories (intravaginal or intraanal), 
delivery devices (e.g., patches, intravaginal rings), aerosols (inhalation), or drops (eye or 
ear); each of these can pose different challenges with regard to disposal; used delivery 
devices, in particular, can contain large amounts of unchanged API. The form of drug 
delivery can greatly affect a patient’s perception, willingness, and comfort in consuming 
the medication. In addition, these forms can be prescribed and dispensed in different 
quantities and using different methods. For example, chronically used drugs can be 
prescribed in quantities sufficient for one course (with approved refills) or multiple 
months (normally 90-day supply). Indeed, many pharmacy chains have promotions that 
encourage increased purchase of certain medications by offering lower prices for a 90- 
day supply or by offering additional OTC medications at drastically reduced prices. 
While certainly this is a convenience to the consumer who will theoretically not have to 
travel to the pharmacy as often to retrieve prescribed medications, the larger supply
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stored in their homes increases the quantity of unused medication in the case of altered 
treatment by their doctor or in the event of their death. Indeed, some mail-order programs 
send automatic refills o f 90-day supplies, leading to a continuing accumulation of unused 
medications upon a patient’s death.
Some medications are dispensed using methods that are intended to improve 
medication usage. For example, birth eontrol pills, usually some combination of 
estrogens and progestagens, are dispensed in unit-dose paekaging. This serves to assist 
the user in adhering to the onee-a-day regimen. Unit-dose dispensing was originally 
designed for hospitals to help reduce medieation dispensing errors. However, there are 
some medieations that are preseribed in the out-patient setting in unit-dose paekaging.
The commonly prescribed “Z-Pak” (azithromycin) is prescribed in a pack of individually 
wrapped tablets -  each corresponding to a day of the week, whieh is the extent of the 
course o f treatment. Methylprednisone, a steroid used to treat chronic inflammatory 
diseases, ean be prescribed in unit-of-use paekaging (Lipowski et al 2002) to encourage 
proper weaning of the patient from steroid use and avoid the complieations of incorrect, 
abrupt discontinuation. Technology for pharmacy repackaging of bulk drugs in unit-dose, 
unit-of-use, or multi-dose strips, together with day and time reminders (ealendar labeling) 
are now available (as one example, see Parata Systems: 
http://www.parata.eom/adhere/index.php).
Finally, dispensing of medication may sometimes be a eonfusing task in light of the
I
many drugs that have similar sounding (and similar spelled) names. Barbella (2008) 
reports that greater than 1,400 commonly prescribed drugs are implieated in drug errors 
due to similar looking drugs or similar sounding names. This is often attributed to poor
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phone communication, poor facsimile quality, and poor penmanship on the part of the 
physician. Dispensing incorrect drugs can lead to pharmaceutical accumulation from 
cessation of therapy due to poor response or the awareness of the error. Much of this 
confusion could be eliminated with widespread adoption of electronic prescribing (“e- 
prescribing”).
Non-Adherence and Non-Compliance
Non-adherence and non-compliance to prescribed treatment regimens is a significant 
and widespread public health issue. Poor compliance and adherence continues to thwart 
and retard efforts by healthcare practitioners to effectively and efficiently treat symptoms 
and progression of a wide spectrum of diseases (NCPIE, 2007).
Research on compliance indicates a wide range o f non-compliance rates. Reported 
non-compliance rates are speeifie for the disease being treated and the treatment itself.
For example, there is a higher incidence of non-compliance for clinical depression and 
for drugs that are prescribed for long-term treatment of a chronic disorder. The World 
Health Organization’s (WHO) 2003 report on adherence to long-term therapies states that 
50% of patients treated for chronic diseases in the US do not take their medication 
properly (and a portion of this is from failure to complete a course o f treatment), 30% of 
all refillable prescriptions are never filled, and 17-20% of all new prescriptions are never 
filled. While failure to fill or refill a prescription does not add to the accumulation of 
leftover drugs, it is possibly an indirect indicator o f failure to complete the prior 
prescription or failure to fully consume free samples; it might also, however, simply 
reflect a physician’s recent change in treatment, which was the most frequent cause of 
returned drugs reported by Langley et al. (2005).
63
Certainly the important factors associated with non-compliance that have been 
identified are the severity of the condition, salience of the condition, and cost and 
misconceptions regarding the therapy. Additional reasons why patients intentionally and 
unintentionally cease treatment are varied as well. They include drugs with difficult or 
awkward delivery systems (i.e., intramuscular or subcutaneous injections), adverse and 
side effects, numerous psychosocial factors (e.g., fear of reliance or addiction), and even 
sensory aversion. Worthington (2007) discusses the positive effect on compliance from a 
drug’s aesthetics, such as its taste, smell, appearance and touch. Pound et al. (2005) 
provide a thorough synthesis of much of the extensive literature on why patients resist, 
avoid, ignore, forget, or alter directions for prescribed medications. The reasons are 
countless and highly complex -  as evidenced by the fact that non-compliance persists in 
being an extremely perplexing and refractory problem faced by medicine. The critical 
importance of better understanding and addressing the numerous aspects of non- 
compliance are emphasized by Rosenow (2005), who has referred to it as the “sixth vital 
sign.”
Patients may decide they do not really need the medication due to misjudgment of 
their health status. This is a difficult obstacle, as many factors can lead to confusion. 
Misjudgment of health status and the need for a medication can also result from diseases 
that do not exhibit obvious signs or symptoms; this can be a disincentive for continued 
treatment. There also may be a breakdown in communication between the prescriber and 
the patient. While physicians may believe they have explained disease and relevant 
physiology of disease and drug mode of action, in reality, patient may not understand and 
become fearful, intimidated, or too anxious to ask the appropriate questions. Another
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reason for poor perception is the overall patient-doctor relationship. Adherence partly 
depends on the prescriber’s ability to communicate the need and utility o f the intended 
treatment. This is turn would depend on the patient’s perception o f the physician’s 
concern, sincerity, and competence.
Locations and Sites in Society Where Medications Accumulate
First-Aid Kits
First-aid kits are probably present in nearly every public building. The Occupational 
Safety and Health Administration (OSHA) require first aid kits to be readily available to 
the public. Therefore, depending upon the size o f the location and the estimated public 
traffic, there may be multiple kits present in the building at any given time. First-aid kits 
are no longer simply bandages, ankle supports, and some gauze. Today, any consumer or 
business organization can purchase first-aid kits that contain anti-diarrheal medications, 
antiemetics, antihistamines, analgesics and antipyretics (e.g., NSAIDs, ibuprofen, 
aspirin), antiseptics and biocides (which include antibiotics), cold tablets, cough syrups 
and drops, antacids, as well as medication for motion sickness, menstrual cramps, and 
stomach upsets. First aid kits are also ubiquitous at a wide spectrum of other venues, such 
as athletic facilities, camps, all forms of transportation (cars, trucks, trains, boats, 
airplanes, etc.), and travelers’ suitcases.
First-aid kits can be specific to the type of institution in which they reside. For 
example, Henry et al. (2006) recommends a school first-aid kit for asthma. Given the 
increasing incidence o f asthma diagnoses in children, it is most certainly prudent for 
educators to be familiar with the disease, it signs, and its management. The recommended
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“asthma first-aid kit” includes a bronchodilator agent. Since first-aid kits are usually used 
sporadically, their contents often reach expiry. Furthermore, kits often must be stored in 
locations that experience high temperatures and therefore their contents can reach expiry 
very fast. Kits supplied by companies are routinely purged o f expired contents, while 
others are replenished on an ad-lib basis. Regardless, the expired drugs are disposed by 
kit-provider personnel usually via the sewerage (personal communications).
Physician Samples
Dispensing and use practices contribute directly to the generation of leftover, 
unwanted pharmaceuticals and may therefore provide opportunities for reducing the 
quantity of waste. One practice that is often overlooked, and often considered only 
beneficial to the patient population, is the use of physician samples. Samples, often called 
“starter packs,” are specifically packaged samples o f drugs provided free by 
pharmaceutical representatives to doctors (a practice termed “sampling”), often as part of 
a marketing strategy or as a means o f gaining access to the doctor. The intention is to 
provide patients with a “starter” supply that will serve to treat in the interim o f receiving 
the prescription at the physician’s office and until the prescription is filled at the 
pharmacy. It is also considered a cost-saving measure since a sample sometimes provides 
the entire course of a short-term treatment or the course of a testing period to assess how 
the patient will respond to the drug before a full prescription is given (thereby avoiding 
the prescribing o f larger quantities that might otherwise never be fully consumed).
I
Firm figures regarding the dollar value of promotions in the US are not available. In 
1999, drug companies gave doctors free medications worth more than $7.2B at retail 
(nearly 10% more than the year before) (Petersen, 2000). The most current analysis.
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however, indicates that promotions in 2004 alone may have a market value ranging up to 
$57.5B, or roughly $61,000 per physician in the US. Samples alone may represent about 
$15B (Gagnon and Lexchin, 2007).
Samples have a number of negative aspects, including personal use by prescribers and 
their families, creation of bias on prescribing habits for newer more costly agents, and 
inappropriate record keeping regarding delivered and dispensed samples (Pai, 2000). 
According to an American Medical Student Association report, the use of samples is 
associated with an influence on the prescription choices and behaviors of the physician 
(Vahia, 2007). Studies have demonstrated that the availability o f free medications is 
considered by physicians when deciding upon a treatment regimen for a patient (Groves 
et al., 2003). Such an effect on physician prescribing behavior would most likely serve to 
sustain or expand the use o f sampling practices.
Physician samples represent opposing forces with regard to medication waste. On the 
one hand, they can eliminate the dispensing of larger quantities of medication that may 
have gone unused. They also certainly do provide treatment and economic benefits to the 
patient. But on the other hand, they have the potential of being a significant source of 
unused pharmaceutical accumulation at the physician’s office or other healthcare 
facilities and have an important potential for drug diversion (US DOJ, 2006). Not only do 
the sample drugs remain unused and eventually expire in physician offices, they can 
accumulate in the possession o f the patients as well. Physicians have no incentive to 
decline sampling, often accepting all that are offered during detailing. At the same time, 
patients have little incentive to decline the offer o f free samples from the physician, even 
if they doubt they will ever use them. There is no requirement for physicians to maintain
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an inventory and therefore, as opposed to pharmacies, there is no real measure o f  how 
many samples are required for the number of patients and types of maladies seen in a 
particular physician office. Consequently, samples will go unused and will eventually 
expire in the physician’s sample closet. Pharmaceutical representatives do not accept the 
return o f the samples, so they must eventually be disposed of by the office. The disposal 
will most likely be via the trash because the packaging (which is usually of unit-dispense 
design) would impede easy and convenient disposal via the sewage system. Few 
published studies have assessed the extent of accumulation of expired sample medication 
or the means of disposal by physician offices. In a single Canadian study, the population 
of a single hospital was invited to return medications over a 2-day period, during which 
time 47 kg of medications were collected from 25 people (Nguyen et al., 2002). Over 
87% of the wholesale value of the collected medications came from physician samples 
(valued over C$1,400 per physician); the bulk of these samples were medications for 
treatment of cardiovascular, CNS, and women's health. At least in one instance, the 
"Code of Marketing Practices" for Canada’s Research-Based Pharmaceutical Companies 
(Rx&D, 2004), guidance does exist for the disposal of "clinical evaluation package" 
(CEPs): "Companies are responsible for making sure that all excess and/or expired CEPs 
of their own manufacture are returned to the company’s storehouse or head office."
When samples are dispensed to patients they too may be destined for accumulation 
and eventual disposal. Samples are given so that a patient may “try out” a medication, 
often with unclear instructions. This unclear directive compounded by the distinct 
difference of a physician’s formal “prescription,” in that it is often given in random 
amounts, may prompt the patient to not necessarily consume as directed. In fact, sample
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packages usually do not have directions on how to take the drug as opposed to the labels 
on dispensed medications. Patients may not understand how to properly consume the 
drug and may therefore be discouraged to use them. These unused drugs accumulate in 
household medicine cabinets and may be accessible to others for whom the medication 
might be contraindicated. While there is no research regarding the extent to which drug 
samples accumulate, local coroner data (Ruhoy and Daughton, 2007) here revealed the 
presence of unused sample packages with almost 5% of the decedents.
Long-Term Care Facilities
Pharmacists and other healthcare personnel employed by long-term care facilities 
(LTCFs) have expanded responsibilities with regard to dispensing pharmaceuticals to 
residents (and in disposing of leftovers). In addition to providing chronic maintenance 
medications on a daily basis to most, if  not all, facility residents, personnel must be able 
to supply drugs in acute (i.e., pain control, agitation) and emergency situations (i.e., 
advanced cardiac life support), stock emergency medical kits for use by all facility 
healthcare personnel, and collect or receive expired, deteriorated, or recalled medications 
for proper disposal. Thus, pharmacy systems that cover LTCFs must maintain a different 
type and level o f inventory than retail pharmacy locations. Because o f the comprehensive 
distribution system, and by virtue o f the quantities of pharmaceuticals required by this 
population, LTCFs are potentially an important source o f accumulated and unwanted 
medication.
Driven by federal and state requirements and standards (Daughton, 2007), LTCFs 
often dispose of unwanted medications via sewage. There are presently a few studies 
underway to examine and assess pollutant discharge of these healthcare institutions.
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especially from disposed pharmaceuticals. The US EPA Office o f Water 2008 Effluent 
Guidelines Program (US EPA, 2008) aims to complete a health services industry survey 
on the disposition o f unused pharmaceuticals in LTCFs, veterinarian offices, and 
hospitals. In an effort to understand the extent of discharge of pharmaceuticals into water 
and possible environmental effects, this study plans to request that these facilities submit 
data on the quantities and types of medications disposed, and the frequencies of disposal 
via the sink, toilet, or trash. Analysis o f this information could eventually be used to 
inform a national standard for disposal and treatment of unused pharmaceuticals at these 
types o f facilities.
Prison Pharmacy Services
In an effort to service the greater than 2.2 million prisoners in federal, state, and local 
incarceration facilities (US DOJ, 2005), prescription medications were the third largest 
healthcare cost for prison institutions in 2002, behind hospital care and physician and 
clinical services (DHHS, 1990). Pharmaceuticals for inmates are provided by either an 
on-site pharmacy at the particular facility or an outside pharmaceutical company that 
services correctional facilities. The private companies represent a “closed-loop” system 
in which they do not offer retail pharmaceutical services to the public or non-incarcerated 
individuals. This system is not different from the non-incarcerated public per se, but it is 
important in the sense that it maintains its own inventory and distribution system.
In an audit of the Federal Bureau of Prisons Pharmacy Services (US DOJ, 2005),
I
prescription medication costs associated with waste were estimated at $2.81 million in 
2004. This represented 2.54% of the Bureau of Prison’s total medication costs. Almost 
half of the cost associated with pharmaceutical waste was due to the transfer of inmates.
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Transferred inmates are not required to take their medication with them to their new 
facility. These medications are often abandoned in an inmate’s cell or locker. In addition, 
upon transference, without regard to whether the inmate’s drugs have been sent along, an 
inmate automatically receives an additional week’s supply o f each of their prescribed 
medications. The abandoned, unused drugs are disposed of since they cannot be recycled 
and dispensed to another inmate.
Another reason for discarded medications in the prison systems is from regular 
searches o f an inmate’s belongings. Expired medications, and illicit drugs, are 
confiscated during these searches and then disposed. In addition, a Bureau of Prison’s 
policy states that medications are only valid 90 days from date o f issue, regardless o f the 
manufacturer’s expiration date. This results in more frequent and greater quantities than 
normal of drugs requiring disposal.
The categories o f medications taken by incarcerated populations are dominated by 
anti-depressants. Research indicates that approximately one in seven prisoners in western 
countries have psychotic illness or major depression and a greater number suffer from 
more mild psychiatric illnesses, such as personality disorders (Fazel and Danesh, 2002). 
In a 2006 Bureau of Justice Statistics Special Report (US DOJ, 2006), it was estimated 
that at midyear 2005, greater than half of all inmates had a mental health problem, 
defined as major depression, mania, or psychosis. This assessment represented 56% of all 
state prisoners, 45% of all federal prisoners, and 64% of all local jail inmates. The report 
further indicates that 26.8% of state prisoners, 19.5% of federal prisoners, and 14.8% of 
local jail inmates were given prescription drugs to treat their mental illness. The 
frequency o f prescribing of these drugs rose 3% from 1997 to 2004. While the report
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does not specify which drags were prescribed, most likely the drags administered were 
anti-depressants, anti-psychotics, and benzodiazepines.
Household Medicine Cabinets
That drags accumulate in the ubiquitous household medicine cabinet is common 
knowledge. The medicine cabinet usually serves as the focal point for organizations and 
agencies attempting to develop solutions for unwanted drag disposal. Obviously, the 
ultimate reasons for why drags go unwanted and accumulate in the home are because 
consumers choose or are told to not consume the medication, or forget they have them. 
Why they choose to not consume the medications is varied and some reasons originate 
from the healthcare practitioner, some from the patient, and yet still others from the 
medication itself. As much as 60% of all medication prescribed is taken incorrectly, or 
not at all (NCPIE, 1995). This non-compliance includes behaviors such as forgetting to 
take the medication, deliberate under-dosing, and hoarding medications to take later 
(Figure 4). Medications that have the highest rate of non-compliance include 
gastrointestinal agents (84%), osteoporotic agents (82%), anti-arrhythmics (80%), 
pulmonary agents (80%), and Alzheimer’s treatments (75%) (ScriptAssist, 2007).
Although the scope and magnitude o f drag stockpiling in the home are largely 
unknown, coroner inventory data lend some insight as to the types and quantities that 
occur (see Chapter 2 and Ruhoy and Daughton, 2007). One cause of stockpiling is the 
large numbers o f drags (including OTC medications) sometimes stockpiled by addicts 
entering addiction recovery treatment (Lessenger and Feinberg 2008); these stocks must 
all be disposed of at once.
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An emerging indicator o f the significance o f household medicine accumulation as a 
cause and source of drug disposal is the increasing implementation of unused-drug take- 
back events and programs in various states in the US. These take-backs are increasingly 
popular as a local means to collect and dispose of un-wanted drugs, taking the 
responsibility out o f the hands of the consumer. (In contrast to the US, many other 
countries have had large-scale consumer drug “returns” programs in place for quite some 
time; Daughton, 2003b).
At these local take-back events, organizers "will often attempt to record some sort of 
measure of the quantities of medications that have been collected. Usually the measure is 
simply the bulk -weight or volume of the complete medications (often including the 
packaging), providing little idea of the associated quantities of APIs. These bulk 
measures might be useful in roughly comparing the success o f one take-back event to 
another but they provide little data relevant to environmental issues. The types and 
masses of each API are the salient data. Take-back programs could be designed to assess 
the categories and dosage amounts o f the APIs being returned, but this requires 
substantial time, effort, and resources, as calculations must be made for every API in 
each type of medication (Ruhoy and Daughton, 2007). The work o f Braund et al. (2007) 
is one of the few examples of detailed API-based cataloging that can be done at take- 
backs.
Regardless of their limitations, take-back events serve to highlight the need for 
prudent disposal o f accumulated household medications. Each take-back event invariably 
collects numerous types of medications. For example, an event held in Sonoma County, 
California during November 2007 collected 128 non-controlled human medications
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during a 2-hour local event. An event held on June 9, 2007 in the city o f Milwaukee 
collected 2,387 pounds, including some packaging, of non-controlled substances. This 
event, which was done in conjunction with law enforcement and therefore could accept 
the return of controlled substances, collected 985 controlled prescriptions. Group Health 
pharmacies in Seattle collected 2 tons of returned drugs from patients during 
approximately a one-month period (Ervin, 2008). These events and others are 
summarized by an Illinois-Indiana Sea Grant project (IISG, 2007). Many other 
medication disposal programs are underway in communities across the nation.
Take-back events also reveal the difficulties in organizing collections at the local 
level and perhaps the infeasibility o f collections becoming a standard, sustainable method 
of removal of accumulated medications from households. Pharmacies are sometimes 
reticent to participate; law enforcement must be present to allow for collection of 
controlled substances; the public is encouraged to perhaps make trips that would 
otherwise not be made; and hazardous waste handling are required for ultimate disposal 
(via incineration or landfilling). These all impose monetary and labor costs and add to the 
environmental footprint of the overall process.
Perhaps more importantly, state governments are recognizing the need for guidance 
and regulation and are discussing the establishment of state product stewardship 
programs. Several states, such as Washington (HB 2600:
http://wastenotwashington.org/HB2600summary.pdf), Maine (HB 411), Minnesota (HB
I
1959), and Iowa (IAS 579), have passed legislation that authorizes and guides some form 
of a pharmaceutical collection and disposal project. Other states, while spécifie 
legislation has not yet been enacted, have issued public guidelines and educational
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materials. An example of such is the Guidelines for Proper Disposal of Household 
Medication issued by the New Jersey Department of Environmental Protection 
(http://www.state.ni.us/dep/dshw/rrtp/disposal.pdf).
Physician and Dental Offices
Beyond samples given to patients, physician and dental offices maintain particular 
inventories of pharmaceuticals on-site for intra-office procedures performed on patients. 
There are many types of procedures that can be done in the office or clinic setting, and 
the type o f procedure performed depends on the medical or dental specialty of the office. 
The types of drugs needed for these procedures usually consist o f anesthetics, analgesics, 
anti-pyretics, anti-microbials, steroidals, anti-inflammatories, immunosuppressives, and 
cardiovascular (which are usually reserved for emergency scenarios).
Although over time a physician or dentist might develop a reliable assessment of the 
quantities and categories of drugs that are necessary to have on-site so as to avoid having 
excess, each office inevitably has some level of expired drug or drug that is no longer 
required that needs to be disposed. The method of disposal historically has been 
sewerage, office trash, hazardous waste, or sharps disposal.
Veterinarian Offices
As described for physician and dental offices, veterinarian offices also maintain an 
onsite inventory of drugs for intra-office procedures. There are, however, two main 
differences. First, veterinary offices also serve as surgical centers for animals. So the 
procedures performed are more invasive and intensive and therefore often require at least 
greater quantities of most o f the categories of pharmaceuticals required for human 
therapy (but often the APIs are unique and specific for veterinary use), as well as
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additional categories and higher potency drugs; veterinary offices also employ unique 
categories, such as medications for euthanasia. Second, veterinarian offices usually 
maintain their own pharmacies for filling outpatient prescriptions. So they face the same 
problems as do human consumer pharmacies. Veterinary offices that practice animal 
euthanasia can inadvertently dispose of hazardous anesthetics by way of improper 
disposal of carcasses, which can lead to acute poisonings of raptors and other scavengers 
(Daughton, 2007).
Cruise Ships
Cruise ships generate and discharge multiple types of waste to the aquatic 
environment, including sewage, graywater, hazardous wastes, oily bilge water, ballast 
water, and solid waste (CRS, 2005). These wastes, if  not properly treated and disposed 
of, can be a source of aquatic contaminants with the potential to threaten human health 
and damage aquatic life. While there are many other types of shipping industries that 
generate particular waste streams, with regard to public consumption and use of 
pharmaceuticals, cruise ships are the major source. A 2005 Congressional Research 
Service (CRS) report on cruise ship pollution for Congress categorized pharmaceutical 
waste from cruise ships as hazardous pollution (Copeland, 2005).
In 2000, a volunteer, independent science panel convened by the Ocean Conservation 
and Tourism Alliance (OCTA) was asked to evaluate the management practices for cruise 
ship wastewater discharges, and to recommend guidelines for good and improved 
practices to the International Council of Cruise Lines (ICCL). Their report recognized 
prescription and non-prescription drugs as a class of water contaminants o f growing
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concern and recommended the Conned establish proeedures that are eongruent with the 
US Environmental Protection Agency’s policies for waste disposal.
Waste generated from cruise liners has been recognized in the past. The ICCL set 
forth 2001 industry waste management practices and procedures in the ICCL Standard E- 
1-01 (Revision 3), revised in 2005 (Copeland, 2005). The Standard recognized that cruise 
ships store and carry various pharmaceuticals, depending on the destination and 
passenger population; they usually consist of both prescribed and over-the-counter 
medications. The document further describes particular handling methods: establishment 
of a reverse distribution system for returning unexpired, unopened, non-narcotic drugs to 
the issuing vendor, witnessed destruction o f narcotic drugs, obeying state waste 
regulations for disposal of unused drugs aboard the ship at time of docking, and onboard 
incineration of other non-narcotic drugs.
Currently, there are no accessible data regarding the quantities or categories of the 
pharmaceuticals commonly onboard cruise ships and to what extent they go unused and 
are in need of disposal or return. However, the nature of the cruise line business is such 
that it would not be unexpected that a large amount of the drugs maintained onboard 
would go unused since they are only present for health-care exigencies with passengers. 
The onboard pharmacies are not intended to treat or manage chronic disease, but mainly 
to support acute medical needs of their passengers.
Abandoned Pharmaceuticals
Many of the sites and locations so far discussed may also be subject to the intentional 
or unintentional abandonment of pharmaceuticals by their intended user. For example, 
vacationers may forget to repack their medications after their cruise experience, and
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children may bring their medicines to school and forget to return them home at the end o f  
the day.
In addition, patients often have medications on their person when being admitted for a 
hospital stay but hospital policies dictate that the patient must use the medication 
administered by hospital pharmacy service and hospital personnel. This is to ensure 
safety and proper treatment for the acute illness, as well as any chronic illness the patient 
may suffer from. At the time o f discharge, a patient will often forget to retrieve their 
medicinal belongings and effectively abandon these drugs at the hospital.
Perhaps more commonly are the drugs unintentionally left behind at various vacation 
spots. While there is no reportable data on the subject, hotels, motels, and lodges 
undoubtedly find and dispose of medications left behind from vacationers 
Armed Forces '
The US Department o f Defense (DoD) maintains its own pharmaceutical supply and 
distribution and its own process for return and disposal of unused medications to support 
and serve the military population. All DoD facilities, including the fleet, purchase 
pharmaceuticals from the Defense Supply Center Philadelphia (DSCP) prime vendor 
program. DSCP contracts with wholesalers to provide the drugs and delivery to the 
customers.
Expired, unopened, and unused drugs are shipped to contractors specializing in the 
recovery o f credits for unused or unopened expired drugs and subsequently use those
i
credits to replenish their stock. The military customers receive partial' credit for the return 
of these drugs. Opened and unused drugs, on the other hand, are incinerated by licensed 
contractors, who contract with DSCP. If the drugs are considered hazardous or controlled
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substances, the contractors are required to provide documentation of where and when the 
destruction took place. Classes and doses of the drugs are not documented. Because the 
military maintains its own closed and organized system, sewerage and landfill disposal 
apparently does not take place on a regular basis at military sites. While this system 
seems to not significantly contribute to the problem of the accumulation of unwanted 
medications, it is important to acknowledge the potential of its contribution. There are 
approximately 1.4 million active members of the military (http://www.census.gov/Press- 
Release/www/2003/cb03 -ffD4se.html). If there were no effective system for removing 
unused pharmaceuticals, the quantity o f unused drugs that would potentially accumulate 
would be significant. It may be a helpful exercise to consider the implementation o f the 
military system for unused medicine disposal in civilian sites as well. The ongoing 
DoD/FDA Shelf Life Extension Program (SEEP) performs testing on various products to 




Coroner offices were recently shown to perhaps be the only ready source o f data on 
drug disposal in the US (see Chapter 2 and Ruhoy and Daughton, 2007). They also 
represent a previously unrecognized source of disposal themselves. In this work is 
compiled a rich data set on the types, frequencies, and quantities of APIs found by 
medical investigators and then disposed into sewage. These data are particularly valuable 
because they represent known input for individual APIs over a defined time frame to 
particular sewage treatment plants (STPs). This allows calculations o f influent
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concentrations (averaged over time) for STPs. In Table 4, however, is presented some 
summary data showing the therapeutic-class distribution of nearly 400 distinct APIs that 
had been disposed to several known STPs over a defined period of time. This is the first 
time that a sufficiently rich set of data have been compiled to allow for meaningful 
categorization of data according to therapeutic class (according to the Anatomical 
Therapeutic Chemical system: ATC). A major unknown and point of debate is the extent 
to which disposal of medicines contributes to the levels of APIs detected in waterways, 
which is a function of the types and quantities of medications disposed, the route of 
disposal, the route of administration (topically applied drugs can be efficiently washed 
from the body and essentially serve as disposed drugs), type o f packaging, and the extent 
to which any given API is metabolized (which dictates the relative contributions by 
excretion). An even greater unknown is the relative contributions of APIs among the 
various types of locations from which they are disposed. In order to properly examine 
this question, reliable and verifiable data are necessary for each o f these variables. 
Historically, it has been difficult to determine what drugs, if  any, were discarded into the 
toilet or trash, and in what absolute and relative quantities. The lack of information is 
mainly due to the absence o f any reporting system. Historically, the advice from 
healthcare personnel and pharmacists has been to simply discard unwanted medications 
via the sewer or the garbage. This practice took place consistently and persistently 




A frequent criticism of focusing on drug disposal as a source contributing to APIs in 
the environment is the lack of understanding o f its overall significance —  which is 
believed by many to be inconsequential. This is primarily a result of the absence of data 
regarding the types and quantities of APIs that are actually disposed during defined 
periods o f time, coupled with a lack of appreciation for the many sources that contribute 
to disposed drugs. This data gap was the primary driver behind Chapter 2 which uses 
coroner inventory data to collect real-world disposal data from known segments of the 
population (see also Ruhoy and Daughton, 2007).
Regardless o f what fraction of individual or total APIs in the environment originate 
from disposal o f unused drugs, it is important to note that it is not just the quantities of 
APIs introduced to the environment that would be important with regard to their potential 
environmental impact. Also of importance, but rarely mentioned, would be any temporal 
or spatial characteristics of their release that differs from the continual but low-level 
releases resulting from intended use by the general population. Disposal holds the 
potential to introduce transiently high quantities of APIs into sewage (Daughton and 
Ruhoy, accepted 2008).These spikes in concentrations could lead to increased exposure 
for aquatic organisms, for example, should the APIs survive sewage treatment; it may be 
likely that risks could also be increased with respect to the homeostasis of the unique 
assemblages of microbial consortia that exist at each activated sludge sewage treatment 
facility.
There are several aspects unique to the purposeful disposal of drugs by flushing 
compared with the unintentional release (via excretion and bathing) of APIs resulting
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from their designed therapeutic usage that could prove significant with respect to 
environmental exposure. These aspects serve as additional imperatives for ensuring that 
the disposal o f drugs is environmentally sound.
The factors controlling drug wastage and leading to disposal are numerous, varied, 
widespread, and complex. Although this analysis could be used to ensure that the design 
of programs for collecting leftover drugs is better informed, approaches for leftover drug 
control such as local take-backs or other types of local “collections” may not succeed in 
efficiently capturing stored medications in a timely manner (to reduce accidental 
poisonings). These programs also have significant sustained costs. A preferred approach 
would prevent the accumulation (and need to dispose) of medications to begin with -  an 
up-stream “green” approach to preventing pollution as opposed to a “down-stream” 
approach directed at controlling pollution. An effective and efficient approach aimed at 
pollution prevention would obviate the need for drug collection programs. Of 
significance is that a holistic pollution prevention approach could also potentially afford a 
number of advantages for healthcare, including improved therapeutic outcomes, reduced 
healthcare expenses, and lower incidence of drug diversion (which facilitates abuse and 
poisonings of humans and animals). The accumulation of medications is a rare instance 
where human health and safety is linked directly with environmental integrity. These 
ideas are embodied in what is termed pharmEcovigilance (Daughton and Ruhoy, 2008).
Take-back events, however, do have the potential to contribute substantial data
i
relevant to the general population. Take-backs can be held in just about any geographic 
area under the appropriate circumstances. They can also be held indefinitely, for as long 
as the organizers are able and willing to participate. These events have the distinct
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advantage of surveying the consumer and inquiring as to why the medicine accumulated 
as well as other parameters regarding the history o f the use and non-use of the 
medication. These drugs can be categorized and counted, and the information can be 
compiled in a database. As mentioned earlier, these events usually simply record the 
weight of the entire collected medication, which often includes packaging. While weight 
can be useful to compare one take-back to another, it does not provide information 
regarding the constituent APIs. Another major limitation of data collected from take- 
backs is that it does not necessarily represent the frequency or rate at which drugs would 
be disposed on a sustained basis (because consumers often stockpile their medications 
over long periods of time for one-time disposal at take-back events). Considering the 
importance of this information, a standardized methodology for collecting data from take- 
back events or returns programs would be useful to environmental scientists, to the 
healthcare and insurance industries, and to regulators. For future studies, a 
recommendation would be that data for APIs from collected drugs be coded according to 
therapeutic class (e.g., using the Anatomical Therapeutic Chemical [ATC] system: 
http://www.fmrc.org.au/atc/index.htm), which would greatly facilitate the sharing and 
intercomparison of data.
By categorizing the coroner drug-disposal data collected by Ruhoy and Daughton 
(2007, unpublished) using the ATC system, it becomes immediately clear that the bulk of 
the API mass disposed (>94%) represented only five of the 14 ATC therapeutic 
categories: Alimentary Tract, Nervous System, Cardiovascular System, Anti-infectives, 
and Musculoskeletal System (Table 2). The other nine categories therefore were 
negligible contributors to the total mass of APIs introduced to the environment by the
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coroner; considerations o f potency would need to be evaluated, however, to eliminate 
these categories as contributors to overall hazard in the aquatic environment.
The major opportunities for pollution prevention are discussed. These opportunities 
are based on minimizing the types and quantities o f drugs dispensed to consumers (or 
how they are made available OTC) as well as altering the consumption and behaviour 
patterns of consumers. Unit dispensing, as opposed to bulk dispensing, has the potential 
to deliver the correct dosage of drug at the correct timing. Already in widespread use in 
healthcare institutions, such as hospitals and LTCFs, unit dosing not only has the 
potential to reduce the inventory o f medications in a patient’s possession, but can also 
reduce medication errors -  whether it is the amount or time of consumption. To perfect a 
method of unit dosing in the retail market may be a perceived obstacle, but technologies 
already exist regarding unit dose re-packaging (e.g., see: Parata Systems: 
http://www.parata.com/adhere/index.php) suitable for use in doctor offices and 
pharmacies. At a minimum, low-quantity prescriptions coupled, if needed, with more 
frequent refills could be encouraged when the need for an ongoing course of treatment is 
not clear, especially when longer-term (e.g., 90-day) prescriptions are being considered.
Trial prescription periods and increased monitoring of patients can only have the 
benefit of improved health outcomes, improved physician-patient relationships, and a 
reduction in the quantities o f unused, unwanted, ineffective, and expired medications. 
Identifying poor compliance and reasons for lack o f adherence will help healthcare 
personnel to adjust treatment or to better counsel the patient accordingly. In addition, 
identifying good compliance can serve to allow the healthcare team to assess
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effectiveness of treatment and adjust as necessary. These steps will assist in reducing the 
accumulation and eventual disposal of unused medications.
The information and evaluation provided here could be used to design the framework 
for a holistic pollution prevention program for medications. Such a program would serve 
an integral role in pharmEcovigilance as conceptualized by Daughton and Ruhoy (2008). 
Designing an effective program will also afford the unusual opportunity for 
collaborations among professionals from the healthcare and environmental science 
communities, which could yield various unanticipated beneficial outcomes.
Numerous factors play roles in the accumulation o f drugs by end-users, whether they 
are healthcare professionals, physicians, patients themselves, veterinarians, farmers, or 
humanitarian relief workers. Expiration of prescribed drugs is a reason for accumulated 
drugs, but numerous other factors play significant roles, including patient non-adherence 
and over-prescribing or excessive purchase; these have been summarized by Daughton 
and Ruhoy (2008). Poor adherence and non-compliance continues to be a major public 
health concern (NCPIE, 2007). Significantly, the number of consumers who do not 
follow medication regimens in the US continues to be substantial, and addressing the 
causes could improve therapeutic outcomes and reduce morbidity and mortality.
Patients will imprudently discontinue medications for a wide variety of reasons, 
including adverse effects, the perceived absence of beneficial effects, inconvenience in 
dosing schedules, change in therapy as prescribed by their physician, or even a poor 
perception of the severity of their illness. See Pound et al. (2008) for an in-depth 
discussion o f compliance.
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Sites where wasted drugs accumulate extend well beyond the household medicine 
cabinet. Some drugs are simply forgotten by consumers at a distant location (i.e., hotels, 
workplace, and hospitals), some are lost track of (e.g., when stored in obscure, alternative 
places to secure them from others), and some are intentionally abandoned. Physician, 
dental, and veterinary offices have supplies o f drugs on hand for intra-office procedures 
and sample dispensing. However, some areas of substantial drug wastage are independent 
of the individual consumer as a patient. These locations are associated with the demands 
and expectations of the public for the easy accessibility and availability o f medications 
should they be needed. Public buildings, vacations areas and maritime vessels, and 
societal institutions such as prison systems and military bases are all locations where 
drugs are stored in large quantities in case the need arises. This ready-as-needed approach 
maximizes the chances that the medication will not be needed, eventually leading to 
expiration and the necessity for their disposal.
The flow chart in Figure 3 represents an overview of the various locations where drug 
buildup and eventual disposal may prove to be significant. It begins with the actual 
production of the pharmaceutical and traces the many places in which’ a drug may end up 
following its purchase, either by prescription, OTC, importation from a foreign country, 
illegal web-based pharmacy, or by other means.
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APIs % of Total
A Alimentary Tract 18,685,27 56 34.6
N Nervous System 16,510,96 95 30.6
C Cardiovascular System 6,331,976 71 11.7
J Anti-infectives 5,608,735 45 10.4
M Musculoskeletal System 3,851,949 21 7.1
R Respiratory System 984,780 16 1.8
B Blood 721,450 9 1.3
V Various 622,800 1 1.2
P Antiparasitics 236,269 2 0.44
L Antineoplastics 186,013 14 0.34
G GenitoUrinary/Sex Hormones 146,440 23 0.27
H Hormonal Preparations 50,601 10 0.09
S Sensory Organs 4,375 1 0.008
D Dermatologicals 3,420 3 0.006
TOTAL 53,945,04 367
Table 2: Summary of API Masses Disposed to Sewerage by a Coroner Office during 
a 12-Month Period^: Categorized by Therapeutic Class^
^Data acquired January-December 2005 from Las Vegas, NV, with a resident 
population o f approximately 1.8 million, and annual visitors o f over 38 million.
Given the thousands o f APIs in commercial use for treating a wide spectrum of 
conditions in both humans and animals, it is critical to have a framework that organizes 
this expanse of potential environmental chemical stressors in a standardized way that 
enhances communication and exchange of data among scientists and also the healthcare 
communities. There are two systems in wide use for categorizing drugs, primarily for the 
continual studies that surround drug utilization. One of these, adopted for the study here, 
is the Anatomical Therapeutic Chemical (ATC) system
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(http://www.fmrc.org.au/atc/index.htm), which is most commonly used outside the US 
but has the advantage in that it uses a more detailed hierarchical system that allows better 
distinguishing between closely related drugs. The ATC system parses all drugs into 14 
different major groups (excluding an “other” category) according to the primary organ or 
physiological system for which they are prescribed; more detailed, lower levels in the 
hierarchy classify according to their chemical or pharmacological properties (such as 
mode or mechanism of action). An analogous system (ATCvet) is in place for veterinary 
drugs. The ATC system is maintained by the WHO Collaborating Centre for Drug 
Statistics Methodology. Every medication is classified according to its primary 
therapeutic use -  classifications composing 14 primary anatomical groups (including the 
category ‘various’ and an additional 15th category for veterinary drugs), followed by 
succeeding detailed subgroups. Every API is listed by only one name -  the International 
Nonproprietary Name (INN), which is the official non-proprietary or generic name 
assigned by WHO to each API (http://www.who.int/medicines/services/inn/en/). An 
analogous classification system (ATCvet system: http://www.whocc.no/atcvet/database/) 
is in place for classification of veterinary medicines. For most APIs, the ATC code is 
used to classify a veterinary product; in these instances, the ATCvet codes are created 
simply by placing the letter Q in front of the ATC code; new ATCvet codes are created 
only for veterinary products whose indications cannot be mapped onto analogous human 
APIs.
UNIT DOSING
Minimizes the quantity dispensed. The evidence that it improves patient adherence 
(and therapeutic outcomes), by ensuring that it will be consumed (and that wastage 
thereby minimized), may be at best marginal (Larsen and Haugbolle, 2007) but still 
equivocal (Connor et al., 2004); this is an important area for further investigation to 
further elucidate its potential benefits.
Ensures proper dosing for optimal healthcare outcome. Automated unit dose on- 
demand dispensers have been expensive and only suited to healthcare within facilities. 
But new technologies are becoming available; as one example, see; Parata Systems: 
http://www.parata.com/adhere/index.php
TRIAL SCRIPTS
Allow for management of ineffective treatment, adverse effects, or poor compliance. 
Necessary before prescribing multi-month supplies.
LOW QUANTITY PACKAGING OF OTC MEDICATIONS
Lessens chance of expiration. Allows consumer to experiment before deciding whether 
a larger quantity is warranted.
INCREASED MONITORING OF PATIENT
Improve patient care and health status by  assessing  effects o f  treatment on both disease  
and patient’s disposition. H elps to identify com pliance issues early in treatment. 
IM PLEM ENT PRAC TIC E OF C O N C O R D A N C E
The concept of concordance was developed in the UK. Its thrust is to actively involve 
the patient in the treatment process, developing mutual trust with the intent of 
improving compliance (Pound et al. 2005); actions include selecting medication and
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dose to minimize side effects (and clearly explaining potential side effects and what to 
do to reduce their occurrence); minimizing numbers of medications; simplifying 
dosage regimens; allowing patient to make adjustments to therapeutic regimens (e.g., 
self-regulation). Indeed, involving the patient seems to be a major avenue toward 
improving patient compliance (van Dulmen et al., 2008). Interaction with the patient 
(especially when multiple physicians are involved) is one of the only ways to 
understand the extent of polypharmacy, a concern that continues to grow (Gorard,
2om%.
FREE SAMPLES AND DONATIONS
Types and quantities maintained at healthcare facilities can be carefully evaluated for 
need prior to acceptance. Assess the patient’s dedication to actually using the samples 
before providing them. Note that physician samples can be donated to charitable 
institutions by licensed practitioners if the samples meet certain criteria (e.g., expiry, 
packaging) set forth in CFR Title 21 (CFR 200). The barriers to donation of leftover 
drugs by consumers are covered by McKee (2006). Various state legislation pertinent 
to drug reuse has been proposed or passed since 2006 (NCSL, 2008).
REDUCE INCENTIVES FOR EXCESSIVE PURCHASING
Implement procedures that would encourage insurance companies and pharmacies to 
re-evaluate procedures for dispensing large quantities of medication that later are never 
used. Better control automatic refills, especially for the deceased.




Release by disposal from just one or a few individuals might result in brief, episodic, 
transient spikes in concentrations of APIs in sewage -  significantly higher than the 
more constant “ambient” levels resulting from the more continual, low-level release of 
APIs via excretion from numerous individuals living in communities served by the 
same sewage treatment plant.
TYPE OF API
The types and quantities of APIs released by disposal will favor certain drugs 
compared with their release by excretion/bathing. One example is those drugs subject 
to abuse and which are recommended to be disposed via flushing. Another example is 
those medications that have universally poor compliance rates (e.g., anti-depressants).
BYPASSING ADME
Disposal by flushing of those APIs that would otherwise undergo extensive 
metabolism before excretion could be a significant source for these particular APIs in 
the environment. The disposal of one dose of carbamazepine (CBZ), for example, 
could contribute the mass of CBZ in the environment comparable to what would result 
from roughly 29-87 ingested doses (calculated from data in Ruhoy and Daughton 
2007; see Chapter 2).
TIMING OF DISPOSAL
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The times of drug disposal can be “compressed” compared with those for 
excretion/bathing. Certain locations (such as LTCFs) often dispose o f drugs en mass 
on particular days or times of day after certain quantities have accumulated. A 
confluence of similar facilities (such as LTCFs) that practice routine drug disposal -  
and which the same STP serves -  could amplify episodic releases. The season of the 
year could also make disposal more significant when those medications that tend to be 
taken during certain seasons are disposed during seasons when their usage is lowest.
LOCATION OF DISPOSAL
Certain drugs are used disproportionately at certain locations (e.g., antipsychotics at 
LTCFs). A confluence of similar facilities (such as LTCFs) that routinely practice drug 
disposal and which are served by the same STP could amplify episodic releases.
Table 4: Unique Aspeets o f Drug Disposal via Flushing (in Contrast with 
Exeretion/Bathing) that Could Prove Environmentally Significant
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CHAPTER 4
MANAGING UNUSED PHARMACEUTICALS -  
A RISK MANAGEMENT PERSPECTIVE
Overview
The fate o f unused pharmaceuticals is poorly understood, although the issue has 
received increasing attention over the past several years. As argues in chapters 2 and 3, 
households are a critical point at which substantial quantities of a variety of 
pharmaceuticals accumulate. These accumulated pharmaceuticals are susceptible to 
undesirable exposures, including accidental misuse, intentional misuse/abuse, 
unauthorized transfer to a third party (e.g. dropping off controlled substances at a 
pharmacy or sharing with a family member or friend), and environmental exposure 
through illegal dumping or disposal to municipal sewers or landfills. Reducing the 
transfer of pharmaceuticals from households to inappropriate locations requires an 
understanding of the factors that promote or minimize acquisition, accumulation, and 
inappropriate use or disposal. Certainly, the efforts to reduce accumulation and 
inappropriate transfer may influence alternative behaviors. Potential undesirable 
outcomes include inadequate medication, a transfer of unused pharmaceuticals from one 
inappropriate disposal to another, and illegal disposal behavior. However, with proper 
monitoring these unfavorable behaviors may be mitigated or avoided.
Chapter two presented some novel data on the contributions and types of 
pharmaceuticals that accumulate at households, based on data from the Clark County
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(Nevada) Coroner’s Office (see also Ruhoy and Daughton, 2007). Chapter three 
cataloged the reasons for, and locations of, accumulation of pharmaceuticals in the US, 
and evaluated the role of a pollution prevention approach to reducing those 
accumulations (see also Ruhoy and Daughton, 2008). This chapter takes a risk 
management approach to further develop the pollution prevention strategy used in 
chapter three for the case of household accumulation of pharmaceuticals.
The risk management perspective is particular helpful in addressing tradeoffs. Risk 
management, which is practiced by everyone from insurance agencies to the Department 
of Homeland Security, distinguishes between the likelihood that things— good or bad—  
will happen, and the extent of the consequences of those good or bad things (see 
Kammen and Hassenzahl, 1999; Hassenzahl and Finkel, 2008). For example, it is true 
that if all the landfills in the US were flooded at the same time, a massive environmental 
release o f pharmaceuticals would ensue. But this is so extremely improbable that it is not 
a scenario worth considering. The risk perspective can be used to frame possibilities, and 
as one-way to help distinguish among different and effective management strategies. 
Central to this approach is to understand the likelihoods of various behaviors, practices, 
and impacts, and the consequences, whether harmful or beneficial, associated with those 
behaviors, practices and impacts.
Outlined here are the key drivers of household accumulation of unwanted 
pharmaceuticals, strategies for reducing such accumulation, and potential unintended 
consequences of changes to those drivers. Reducing undesirable exposures can best be 
accomplished through a strategy that integrates improved prescribing practices, 
information for consumers about prescription compliance and appropriate disposal.
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clarification o f legal disposal options, and changes to chain o f custody that allows and 
regulates return of unused pharmaceuticals to points of purchase. Implementing this 
strategy would require cooperation among a range o f agencies, including the Department 
of Justice, the Food and Drug Administration, the Environmental Protection Agency, and 
the Centers for Disease Control.
Introduction
That pharmaceuticals and their active ingredients exist in our environment, 
particularly our waterways, is now undisputed. The interpretation of their existence, 
however, with regard to risk o f detrimental effects on human and ecological health, is 
poorly understood. Examined and assessed here is the transfer o f pharmaceuticals from 
intended and appropriate locations to unintended and inappropriate locations. Prospective 
options for reducing those transfers and the potential impacts of those transfers are 
explored. Finally, opportunities for additional research on accumulation and transfers that 
would most likely reduce future needs for disposal are proposed.
The presence of pharmaceuticals in the environment is the focus of an ongoing dialog 
among private industries, the public, and governmental agencies. The US market 
accounts for 47.7% of global pharmaceutical sales (IMS, 2006). This lion’s share o f drug 
use has not been without consequence. Concentrations of active pharmaceutical 
ingredients (APIs) have been detected in multiple water systems throughout the country
i
(Daughton, 2001; Kolpin, et al. 2002; Fent et al., 2006) and have been the subject of 
recent local, national, and global media headlines. Researchers in a variety of fields 
continue to assess, analyze, and decipher the extent to which these compounds exist, and
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why they exist, in the nation’s water. Law and policymakers (Crow, 2008) are anxious to 
understand the issue and enact regulations that would serve to not only protect the public 
but address public fears (i.e., SB 966, 2007; MA 2182; HB 3064, 2008). In April 2007, 
the US Senate held a hearing to review federal efforts to assess and regulate drinking 
water contaminants, specifically pharmaceuticals (Argent & Schuster, 2008).
Primary treatment of disease and illness with the use of pharmaceutical medication 
has increased steadily over the past few decades. A 2007 study by Medco Health 
Solutions, Inc. demonstrated 51% of American children and adults were taking one or 
more prescription drugs to treat a disease diagnosed as chronic, or long-term. Since this 
does not correspond to a similar increase in the diagnosis of chronic conditions (Medco 
Health Solution, 2008), by implication, physicians increasingly turn to pharmaceuticals to 
treat and manage ailments. This increase in drug consumption would be expected to 
parallel an increase in the presence of pharmaceutical residues in our water.
The presence of APIs in the environment results from two major sources: excretion 
(and bathing) and disposal. The extent to which each contributes to the relative 
concentrations detected in water systems is unknown and difficult to assess (see Chapter 
2 and Ruhoy and Daughton, 2007). Excretion of any particular medication depends on 
that drug’s pharmacokinetic profile, as some drugs are extensively metabolized, some are 
metabolites or biotransformation byproducts that may have biological activity similar to 
the parent API. The metabolic and physiologic profile of the consumer is another 
important factor in the subsequent excretion of the consumed drug. In most cases, proper 
consumption and natural excretion of a required medication are desired for beneficial 
therapeutic outcomes. However, optimal prescribing patterns and patient compliance may
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reduce the quantity o f  medications that remain unused (see Chapter 3 and Ruhoy and 
Daughton, 2008). They may as well reduce the level of consumption of medications and, 
by extension, the quantity of compounds excreted. Regardless, discarding pills directly 
into sewage systems releases a much higher concentration of drugs into the environment 
than does excretion (Reid, 2007).
Disposal and removal of unwanted drugs can occur through household wastewater 
(toilet and sink), landfill sites (trash), or diversion practices, sometimes referred to as 
“pharming”. These three pathways for unwanted drugs are inappropriate transfers. 
Another major route -  disposal (or amendment) of biosolids on agricultural land, as is 
currently the accepted standard method is another potential inappropriate transfer. 
Pharmaceutical residues have been measured in landfill leachate and therefore have the 
potential of entering the wastewater systems as well (if the leachate is transferred). The 
frequency and quantity o f drugs that are discarded through either system in the US is an 
open question and an area of much needed research.
The predominant method of disposal of unwanted pharmaceuticals, based on small 
surveys both in the US and England, is via household waste and primarily in the trash 
(Bound and Voulvoulis, 2005; Kuspis and Krenzelok, 1996). Chapter 2 explored the 
quantities and categories of drugs discarded, mostly by flushing, by a local coroner 
office. The study demonstrated greater than 102,000,000 mg (102 kg) of various APIs 
disposed in a thirteen-month period for a population of approximately 2 million. To 
further elucidate the extent to which unused pharmaceuticals are discarded, the USEPA’s 
Healthcare Industry Survey is a current project designed to characterize medication 
accumulation and disposal in long-term care facilities (US EPA, 2008).
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The safest method of disposal for unused pharmaceuticals remains unclear. The desire 
to prevent drug residues in the environment can often be in conflict with the inherent 
need to protect public health. Wasted pharmaceuticals that remain in households or other 
potential areas o f accumulation (see Chapter 3 and Ruhoy and Daughton, 2008) are 
readily available to those who seek to misuse, divert, or abuse these medications. 
Prescription drug diversion and the non-medical use of these medications is a current 
public health and safety concern (Inciardi et al., 2007; Lessenger and Feinberg, 2008).
Rates o f abuse o f prescription and over-the-counter medications (OTC) among 
teenagers are very high. Use of hydrocodone, for example, by teens for non-medical 
purposes has been reported for almost 10% of 12‘*' graders (Keuhn, 2007) in the US.
These drugs are also accessible for the potential of accidental poisonings. Deaths due to 
overdoses were reported in significant frequency in death certificate data (Wysowski, 
2007). Deaths from medication mistakes at home increased from 1,132 deaths in 1983 to 
12,426 in 2004 (Johnson, 2008). This concern fostered the 2007 federal guidelines for 
disposal of unwanted medication. These guidelines recommend the disposal of drugs into 
the trash, after first adulterating them, although the APIs remain in their original chemical 
state, and sealing them in a container. A list of drugs with a greater propensity for 
diversion was included with the recommendation for toilet disposal (ONDCP, 2007).
The risk to human morbidity and mortality from exposure to environmental 
concentrations is an area o f active investigation and conversation. Kidd et al (2007) 
demonstrate that aquatic flora and fauna are susceptible to, and possibly adversely 
affected by, pharmaceutical contaminants. Medicines designed for human use may induce 
physiological and pathophysiological effects in aquatic organisms since receptor proteins
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are shared among species, (3-adrenergic receptors, for example (Owen et al., 2007). 
Detrimental effects on wildlife of drugs at concentrations lower than 0.1 ng/1 has been 
demonstrates (D’Ascenzo et al., 2003; Warner and Jenkins, 2007; Boxall, 2004). Human 
exposure to pharmaceuticals through environmental exposures is difficult to assess.
Human exposure to therapeutic doses is obviously not the concern. Aquatic exposure 
rates are at least 100 fold lower than those required to produce minimal therapeutic 
effects in humans (Kostich and Lazorchak, 2008) and environmental and human health 
risk assessments seemingly demonstrate no appreciable immediate adverse effects to 
aquatic environments (Winter MJ et al., 2007) and humans (Schulman et al., 2002; 
Schwab et al., 2005; Daughton, in-press) from exposure to low concentrations.
However, chronic, low-level, involuntary exposures to multitudes of APIs may pose a 
potential risk to human health (Collier, 2007; Daughton, in-press), particularly to 
vulnerable populations (Filby et al., 2007), such as neonates (Grandjean et al., 2007). 
Pharmaceuticals are designed to be biologically active at very low concentrations and are 
approved to treat a specified pathology, not the population at large. In addition, various 
drug-drug interactions are well established in the human body and these interactions may 
play a role in effects due to environmental exposures to pharmaceuticals as well. 
Bioaccumulation and bioconcentration has yet to be quantified and may also result 
exposure levels substantially greater than those measured in the environment (USGS, 
2008).
i
Some APIs, or combinations o f APIs, may present greater toxic concern than others. 
Sanderson et al. (2004) established a predicted rank order o f relative toxicity of four 
classes of pharmaceuticals, while noting that all examined pharmaceuticals have possible
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toxicity. In rank order (from most to least toxic) they are: sex hormones, cardiovascular 
agents, antibiotics, and anti-neoplastics. Some drugs demonstrate considerable mixture 
toxicity, such as additivity or synergy, in combinations with other drugs of the same class 
(Cleuvers, 2004), or o f different classes (DeLange et al., 2006). Kostich and Lazorchak 
(2008) found mutagenic cytotoxic agents display cumulative toxicity and long-term 
effects that appear linearly related to dose. Mixtures of drug compounds at environmental 
levels were found to inhibit growth of human embryonic kidney cells (Thrall, 2006). 
These are important and relevant findings since APIs rarely appear in the environment as 
single agents (Focazio et al., 2008).
Discussion
A four-stage risk management approach
Risk management can be an effective way to deal with complex environmental 
problems. The following paragraphs introduce a 4-stage risk management approach, 
which is then applied to the management of household pharmaceuticals.
A risk management approach takes a broad perspective on exposures to, and effects 
of, a particular hazard. Morgan (1981) describes four alternatives for risk management: 
(1) alter the built or human environment; (2) avoid or modify exposure processes; (3) 
avoid or modify effects processes; and, (4) mitigate or compensate for effects. 
Understanding the process by which the risk takes place can effect minimizing the 
potential risk.
In the case of household accumulation of pharmaceuticals, the hazard analog is the 
transfer of unused pharmaceuticals from appropriate to inappropriate locations. An
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“appropriate” location for pharmaceuticals refers to any location for which 
pharmaceuticals are intended and originally conceptualized, or safe and legal disposal 
endpoints for those that go unused. These locations include manufacturing and 
distributing centers, pharmaeies, sites intended for use in case o f need by different 
segments o f the populations (Ruhoy and Daughton, 2008), and the consumer household 
prior to its directed and expected consumption.
“Appropriateness” also includes a quantitative dimension. So while it is appropriate 
to have pharmaceuticals present in pharmacies and perhaps in physician offices, it is also 
important that the amounts of the drugs residing in these otherwise appropriate locations 
would be the minimal amount required to fulfill their intended roles -  in other words, 
their “appropriate” roles.
"Inappropriate" locations, therefore, refers to those locations where pharmaceuticals 
reside without the apparent objective o f intended use and consumption. In some cases, 
these locations may be similar to the locations deemed “appropriate” (indeed, a single 
location may simultaneously be appropriate for some pharmaceuticals yet inappropriate 
for others). Once drugs become unwanted or unusable, either due to expiry, intolerable 
effects, or patient non-compliance, they are considered pharmaceutical waste and their 
residence beeomes an inappropriate location. In addition, excessive production and stock 
of otherwise “appropriate” locations, such as distribution centers, pharmacies, physician 
offices, and pharmaceutical representative inventory results in the presence of drugs in an 
“inappropriate” location since their supply is not met by patient demand. Finally, 
“inappropriate” locations would almost obviously include any site that may possess 
medications in an illegal, immoral, or unethical manner.
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From the risk management perspective, dealing with unused pharmaceuticals can be 
conceptualized in four stages: (1) alter the ways in which pharmaceuticals arrive at 
accumulation location; (2) avoid or modify the extent to which pharmaceuticals that 
arrive are allowed to accumulate; (3) avoid or modify the extent to which accumulated 
pharmaceuticals are transferred from appropriate to inappropriate locations (or between 
inappropriate locations); (4) mitigate or compensate for the effects of unused 
pharmaceuticals once transferred to inappropriate locations. This discussion focuses 
mainly on the household medicine cabinet with some ancillary discussion points 
regarding other locations. “Medicine cabinet” here is a catchall phrase; medicines are 
stored in a range of locations within a household, and often in multiple locations within a 
single household.
Pharmaceuticals are designed to treat human maladies and their deliberate context is 
to be prescribed for a patient in order to alleviate symptoms, improve quality of live, 
enhance lifestyle, ameliorate disease, or prolong life. Once pharmaceuticals are unused 
and unwanted they are then technically in an inappropriate location even though it is 
possible they were originally appropriately located. This inappropriate location may place 
the public in danger as these drugs may be accessible and available for intentional misuse 
and abuse or for unintentional usage, including dermal and pulmonary exposure, as well 
as ingestion. From this inappropriate location, these drugs are inappropriately transferred 
to another inappropriate location, with potentially greater adverse environmental impact. 
For example, an unwanted drug may be transferred from the household, which exposes a 
limited number of people to its accumulation, to an area of broader exposure potential, 
such as natural systems.
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Wasted dmgs are disposed of either via household trash, toilet, sink; through 
accidental ingestion; or by intended diversion, that is, the inappropriate transfer to 
another for whom the medication was not prescribed. In the case of controlled 
substances, this final scenario would violate the Controlled Substance Act (CSA) 
enforced by the US Drug Enforcement Administration (DBA) that prohibits the transfer 
of all controlled medication beyond the prescribee, even a physician or a pharmacist. In 
addition, the diversion o f these substances contributes to dmg addiction, as these dmgs 
are often re-sold to those who seek to misuse these prescription dmgs. Even in the case of 
non-controlled substances, transference would violate FDA mandates (US FDA, 1988) 
and place untold number of consumers in danger as all medication has the potential to 
cause toxic reactions under certain circumstances.
In many locations, medications disposed into the toilet enter the seWerage systems. 
From there they are treated in the sewage treatment plant (STP) and eventually result in 
treated sludge dispersed on fields, treated sewage released into the aquatic environment, 
or treated sewage injected into the ground. It is important to note that raw sewage is also 
frequently released -  on purpose and by accident. Therefore, the pharmaceuticals 
entrained in such sewage have the potential to result in exposures to both terrestrial and 
aquatic organisms. Indeed, reproductive, endocrine, development, and behavioral effects 
on aquatic organisms have been reported.
Medications disposed into the household trash are collected by municipal waste
I
handlers and are eventually (if not diverted by pharming or wildlife) disposed in landfill 
systems or incinerated. While not directly injected into wastewater, these pharmaceuticals 
have the potential for long-term persistence and eventual transport into ground water.
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Pharmaceutical compounds have been detected in leachate samples from municipal 
landfills (Barnes et al. 2004). Lee and Jones-Lee (1998) suggest that older landfills with 
liners have poor groundwater monitoring systems and are unreliable. The latest 
geoengineered landfills collect the leachate and either treats it on-site or it is transported 
to an STP. Either way, treated effluent is often discharged into receiving streams.
Pharmaceuticals that remain in the household are available for accidental ingestion 
and potential subsequent poisoning. Unintentional pharmaceutical poisonings of children 
results in tragic and unnecessary morbidity and mortality each year. In 2005, according to 
the American Association of Poison Control Centers (AAPCC), o f the almost 2,500,000 
human exposures reported, 64.5% were reported to be children under the age o f 20 years 
and 50.9% under the age of 6. This group o f children and adolescents also accounted for 
9% of the 1,261 fatalities due to poison exposure. The majority o f these pediatric and 
adolescent fatalities were the result of intentional exposures -  suicide, misuse, and abuse 
-  to drugs. O f the reported deaths in children younger than six years o f age, 16 were 
known to be unintentional. O f the 14 medication-associated deaths, 13 were from 
exposures to prescription medication, 5 o f  which contained opioids.
Finally, pharmaceuticals that are allowed to accumulate in inappropriate locations are 
accessible to those who seek to misuse, divert, or abuse these drugs. According to the 
National Center on Addiction and Substance Abuse at Columbia University (CASA), 
between 1992 and 2003, while the US population increased 13% and the number of 
prescriptions written for non-controlled drugs increased 57%, the number o f prescriptions 
filled for controlled drugs increased 154%. During the same period, there was a 90% 
increase in the number o f people who admitted abusing controlled prescription drugs.
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Alarmingly, there was a 203% inerease among 12- to 17-year olds (212% by 2003) and a 
78% increase among those greater than 18-years old (81% by 2003).
CASA reports that the 15.1 million Amerieans abusing eontrolled preseription drugs 
exeeed the eombined number abusing eoeaine (5.9 million), hallueinogens (4.0 million), 
inhalants (2.1 million), and heroin (.3 million). The use of alprazolam, oxyeodone, and 
methylphenidate by teens (ages 1 2 -1 7 )  inereased 212% between 1992 and 2003. In 
2003, 15% of teens abused or were addieted to eontrolled drugs, with opioids, CNS 
depressants, and stimulants being the most frequently reported.
Aeeording to the Drug Abuse Warning Network (DAWN), in 2005 there were almost 
600,000 visits to US hospital emergeney departments due to non-medieal use of 
pharmaeeutieals (e.g., reereational or unintentional use). This represents a greater than 
20% inerease from 2004. Bentur et al. (2004) found 84% of deliberate self-poisonings in 
the study population involved pharmaeeutieals.
The following paragraphs develop the key factors that determine the impact or 
importance o f eaeh of the four risk management stages for the ease of household 
aeeumulation, as operationalized for the ease o f household pharmaeeutieals. For eaeh 
stage, some key faetors, and their implieations, are outlined in Table 7. The hazard in this 
ease is defined as transfer from appropriate loeation to inappropriate loeation. For eaeh of 
the four risk management stages, understanding the faetors that determine whether that 
stage is more or less likely to inerease impaets is worthwhile. A detailed eomparison 
aeross the four stages, then, eould elarify the relative eeonomie and ethieal advantages 
and disadvantages of different strategies to minimize sueh transfers. Sueh a eomparison, 
however, is beyond the seope of this dissertation.
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Stage one interventions are those that prevent medicines that are not going to be used 
from arriving at the household in the first place. It encompasses the conditions that lead 
to the presence o f pharmaceuticals in household locations following the manufacture, 
distribution, prescribing, dispensing, and purchase. To the extent that pharmaceutical 
prescribing and purchase leads to pharmaceutical accumulation in the home, steps can be 
taken to reduce the ultimate quantities of drugs that go unused and accumulate in the 
home and then require disposal. These steps include alternative methods of managing 
disease, effective and efficient prescribing practices, and reductions in incentives for 
excessive purchasing. Many of these considerations fall under the “pollution prevention” 
concept discussed in detail in Chapter 3 and Ruhoy and Daughton (2008).
The strategy to manage stage two, which is the minimization of pharmaceuticals that 
will not be used, is to improve patient compliance and adherence with prescribed 
treatment regimens. Improved compliance may ultimately result in reduced quantities of 
drugs that go unused. However, it is important in considering this to simultaneously 
avoid encouraging patients to take medications that have been purchased but which turn 
out not to be useful, necessary, or to cause unintended effects.
Stage three considers strategies for prudent and safe methods of disposal of 
pharmaceuticals that inevitably go unused. This stage encompasses those steps that must 
be taken as a society to ensure proper stewardship o f the products that are manufactured 
by producers as well as the products that are purchased by consumers. Central to this 
stage is to improve patient awareness o f the need to appropriately dispose o f unused 
pharmaceuticals, and of the opportunities for appropriate disposal options. To the extent 
that appropriate disposal options are not readily available, stage three will also include
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adding or improving disposal alternatives. Bound et al. (2005) suggest that environmental 
awareness and the perception of risk may have a positive impact on the motivation of the 
consumer to follow prudent disposal recommendations.
Stage four involves means of lessening the impact o f environmental and human fate 
of pharmaceutical residues, such as treatment technologies. It includes technologies to 
remove pharmaceuticals from water or landfills, law enforcement efforts to prevent 
pharming or resale of medicines, clinical treatment or remediation for harm caused, or 
financial compensation for harms.
Significantly, the use of the four stages is an organizing heuristic: in reality, there is 
not always a clear differentiation among the stages. Further, interventions at one stage 
might have ripple effects on other stages. For example, charging pharmaceutical 
companies a penalty if  their products are found in the environment is a fourth stage 
intervention. However, expecting such penalties might lead those companies to take 
preemptive actions most under their control. They might develop new distribution 
practices (a first stage intervention), or develop take-back strategies (a second stage 
intervention). Thus, while the discussion here is couched in terms of the four stages, it 







1 Modify the natural 
or human 
environment
Modify likelihood that 
households will acquire 
pharmaceuticals that will 





2 Avoid or modify 
exposure process






consumption of prescribed 
pharmaceuticals
3 Avoid or modify 
effects process
Modify likelihood of 
successful transfer of 
unused pharmaceuticals 
to an appropriate location
Facilitate transfer of unused 
pharmaceuticals to 
appropriate endpoints




Educate patients on 
appropriate disposal 
options
4 Mitigate or 
compensate for 
effects
Modify likelihood that 
pharmaceuticals 
transferred to an 
inappropriate location 
will have an adverse 
impact
Mitigate impacts of unused 
pharmaceuticals that have 
been transferred to an 
inappropriate location OR 
compensate for those 
impacts.
Develop sewage treatment 
systems that remove 
pharmaceuticals
Charge fees to patients, 
pharmaceutical companies 
or others for inappropriate 
transfers
Table 5: Strategies to Abate the Risk of Transfer of Pharmaceuticals from Households to 
Inappropriate Locations
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As an example, fluoxetine is a commonly prescribed selective serotonin reuptake 
inhibitor (SSRI) that has been detected in surface waters (Kolpin et ah, 2002). It is used 
to treat patients with clinical and sub-clinical depression. Non-compliance for 
antidepressant therapy is particularly high, both because of the effect on mood and 
motivation of the disease and because of the nature o f chronic medication use. Keene et 
al. (2005) estimated 54% of patients become noncompliant during SSRI therapy. Indeed, 
in the Clark County (Nevada) Coroner data alone, approximately 67,250 mg of fluoxetine 
were identified in the homes of the decedents for the 13-month study period.
Fluoxetine has been shown to cause growth impairment in frogs (Holmes, 2003), 
behavioural alterations in invertebrates (DeLange et al., 2006), and have the potential for 
toxicity to other aquatic organisms (Johnson et al., 2007). Fluoxetine is almost 
completely removed from wastewater influents with advanced technologies such as 
ozonation (Snyder et al., 2006), but may be less effectively removed during treatment 
with less advanced and older technologies, such as membrane bioreactor systems (Snyder 
et al., 2005).
Risk management strategies as outlined by the four stages and with regards to the 
example o f fluoxetine, might consist of: (1) directing patient to alternative treatment 
plans for the depression, such as behavioral modification therapy, homeopathic and 
naturopathic remedies, or lifestyle changes, particularly patients with minor and not 
major depression; (2) increased management and follow-up of patient to assess and 
improve upon adherence to medication treatment plan; (3) educating patients on safe 
methods of disposal, whether these be guidelines by federal organizations, state-specific 
waste handling regulations, or locally available take-back programs or returns; and (4)
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improved technology regarding the removal and transformation o f fluoxetine and its 
metabolites in water as well as increased resources dedicated to study the effects of the 
unintended human exposure to fluoxetine in the environment.
First Stage
The first stage is the arrival (or not) at a household of pharmaceuticals that, for one 
reason or another, will not be used as intended (table 5, row 2). Stage one is where one 
can modify the likelihood that households will acquire pharmaceuticals that will not 
eventually be used. Management strategies minimize acquisition of pharmaceuticals that 
will not be used at households, The distinction between appropriate and inappropriate 
locations for pharmaceuticals must begin with the acknowledgment of the appropriate use 
and transfer of pharmaceuticals. Pharmaceuticals designed for human use save lives and 
ameliorate symptoms so as to provide millions of people with an improved quality of life. 
They improve health outcome and many of these medications have prevented untold 
levels of human epidemics and demise. A relatively recent class of pharmaceuticals and 
one with expanding sales includes those designed for elective usage by the consumer for 
lifestyle purposes, such as cosmetic and aesthetic use. Elective usage implies not 
primarily directed by a physician but by the patient. This may lead to prescriptions that 
would otherwise not have been written.
Pharmaceuticals that are optimally and appropriately prescribed to patients are 
dispensed and ultimately arrive at appropriate locations, such as the consumer household. 
Chapter 3 (see also Ruhoy and Daughton, 2008) explored various methods physicians 
and pharmacists may use to help minimize wasted pharmaceuticals and therefore by 
extension the inappropriate transfer of medication to inappropriate locations. These
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recommendations would serve to improve health outcomes and health care resource 
management as well. As the field of medicine progresses, physicians may be better able 
to tailor treatment regimens for genetic variants of individual patients.
Genetic medicine is quickly becoming an important emerging discipline in clinical 
medicine. The practice o f pharmacogenetics utilizes individual genetic information to 
improve the efficacy o f the treatment selected. “Rational drug design” (Yildirim et al., 
2007) would take into account individual and disease-specific protein targets for better 
treatment response. Tests to determine genetic variations and genetic profile are 
becoming increasingly popular and requested (Katsanis et al., 2008). As this practice 
improves and increases, the optimal treatment may be prescribed for a patient and this 
may not only improve compliance, but also will most likely minimize the quantity of 
medications prescribed and dispensed during the course of treatment.
Optimal prescribing patterns are complex to assess and even more difficult to 
implement. Optimal prescribing patterns would take into account not only the most 
effective medication in terms of biochemical and biophysical effects on the disease 
course of the patient, but also takes into consideration the behavioral patterns of that 
individual patient. The decision on what to prescribe can be based on many factors. For 
example, the consistence presence of drug samples influenced physicians to prescribe 
drugs that differed from their “preferred” drug choice (Chew et al., 2000).
Non-compliance with treatment regimens can have significant public health
i
implications. It is not part of standard training for a physician to assess the probability of 
compliance by that patient and in any case, the information is not readily available. 
Literature on compliance studies indicates it would depend not only on the medication
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and the disease being treated, but personality characteristics and socioeconomic factors of 
that patient (Ellis, 2000). Yet decreased accumulation of pharmaceuticals in appropriate 
locations would require an understanding o f the probability of proper compliance by an 
individual patient. Otherwise, even the most effective and efficiently prescribed 
medication would ultimately go unused.
Regardless, it is important for physicians and other prescribing health care 
professionals to minimizing the transfer, or the arrival, of pharmaceuticals most likely to 
go unused to appropriate locations. Focusing on the household, there are many options 
for the reduction of this transfer, such as unit dosing, trial scripts, and reduction in the use 
of samples.
Second Stage
The second stage is the success or failure of patients to use prescribed 
pharmaceuticals as intended (table 5, row 3). Stage two is where one can modify 
likelihood that acquired pharmaceuticals will be used. Management strategies promote 
appropriate consumption of prescribed pharmaceuticals. Factors that reduce or increase 
the amounts o f unused pharmaceuticals that accumulate and are therefore at risk of 
inappropriate transfer are varied. Most reasons focus on directed or undirected behaviors 
by consumers. Compliance with prescribed medication regimens is a problem most 
physicians face in their practice. There are many reasons why patients discontinue 
treatment. Some o f these reasons are valid, such as intolerable effects or a change in 
severity/course o f the disease process, and may even be physician directed, such as 
change in treatment plan due to adverse events or ineffectiveness.
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However, often a patient will cease taking prescribed medication either partially or 
completely. The potential for non-compliance depends upon not only individual, and life 
choices they are confronted with, but also with the medication itself. Some medications 
require complicated consumption directions, either with frequency, timing, dosing, or co­
consumption with other products, such as food or drug products. Other medications 
require knowledge of difficult delivery systems, such as inhalers or syringes. Finally, 
some medications result in expected, but adverse effects, which will likely lead to poor 
motivation on the part of the patient to consume the medication. Regardless, non- 
compliance and non-adherence will lead to accumulated drugs.
Compliance rates in the literature can range anywhere from 0% to 100%, depending 
on the patient, the disease under treatment or the treatment itself. Studies have identified 
particular personality traits that may have a higher incidence o f non-compliance (Cohen 
et al., 2004). These traits are not always obvious during a typical physician visit and 
therefore may go unnoticed and unattended by the prescribing physician. Patients may 
also not recognize the severity of their disease and the importance o f their medication to 
prevent and forestall further progression and morbidity.
Some disease processes themselves can present difficulties for the patient to follow 
treatment plans. Fatigue, myalgias, neuralgias, paralysis, and depression can all result 
from disease and may leave the patient unmotivated, or incapable, to access medication.
It is not without surprise that there is a high non-compliance rate with anti-depressant 
medications.
Cessation of treatment can also result from physician-directed alterations in the 
treatment plan. Side effects, adverse effects, or intolerable effects of medication are often
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valid reasons for exchanging the current plan for a new one, with the resultant leftover 
medication. Treatment can also be halted because the desired effects are not appreciable 
and the disease course requires intervention.
Third Stage
The third stage is the failure or success o f consumers to transfer unused 
pharmaceuticals to appropriate locations (table 5, row 4). Stage three is where one can 
modify likelihood of successful transfer of unused pharmaceuticals to an appropriate 
location. Management strategies facilitate transfer of unused pharmaceuticals to 
appropriate endpoints. A range of technical, legal and informational constraints limit the 
available strategies at this stage. The term “appropriate” thus includes several 
dimensions, including whether the location is secure in the sense of minimizing release to 
humans and / or the environment, as well as whether it is legal to make the transfer. 
Likewise, consumers may have no or limited knowledge about which transfer endpoints 
are appropriate and which are inappropriate.
Locating, identifying, and quantifying accumulated unwanted pharmaceuticals in all 
locations beyond the household medicine cabinet and healthcare facilities would serve to 
prevent the eventual routine need for disposal of these expired and otherwise unusable 
drugs into the environment. A centralized system of inventorying and monitoring all 
systems and locations where pharmaceutical compounds are dispensed and distributed 
could ensure their proper collection and disposal.
Secure locations would ensure public and environmental safety. These sites would 
prevent both humans and pets from inadvertently or intentionally accessing unused drugs. 
Law enforcement organizations would be the ideal location for unwanted medication
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storage. These sites are protected from the public, and at the same time staffed with 
personnel charged with protecting the public. Currently, police officers are permitted to 
confiscate pharmaceuticals that are seized during the act o f apprehending criminals and 
during criminal investigations. Extension o f this standard to include all areas of law 
enforcement, such as state and federal Drug Enforcement Administration personnel, to 
accept unwanted pharmaceuticals from their respective communities would offer sites for 
medication drop-off.
Since the CSA prohibits the possession of controlled substances by anyone other than 
the end-user, it is difficult to devise a strategy for a centralized storage o f unused drugs 
since it is not feasible to consider only medications that are not controlled. Consumers 
often are not familiar with the medications they are prescribed much less whether they 
are considered controlled substances. Therefore, law enforcement would serve to protect 
the public from diversion by housing those substances most vulnerable to acts of crime 
and abuse. At the same time, environmental safety would be preserved, as pharmaceutical 
waste residues would be prevented from entering natural systems.
Collection events at locations such as pharmacies and government edifices are a good 
alternative for at least the collection of these drugs, if  not final storage. The issues once 
again surround the enforcement o f the CSA. If collection events can have law 
enforcement involvement, they may able to circumvent the problem of accepting 
controlled substances. O f note, the US EPA Office of Child Health and Protection has
i
issued a grant to the University of Maine for a mail-back pilot prograhii Consumers are 
given envelopes with their prescriptions in which they return unused medications. These
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drugs are mailed to the Maine DEA who collects and stores the medications for later 
disposal by incineration after transport by reverse distributors.
While awareness is increasing thanks to many programs as well as media interest, 
consumers are still unsure of what to do with their unused pharmaceuticals. Certainly, 
some local areas are more active and have held well-publicized take-back events. Yet 
nationally the public remains contused. There does not exist a consensus of a 
standardized solution or a generally accepted method of disposal. Further research to 
decide safe and prudent methods o f disposal is warranted.
Fourth Stage
The fourth and final stage is the mitigation of and/or compensation for impacts of 
pharmaceuticals that have been inappropriately transferred (table 5, row 5). Stage four is 
where one can modify the likelihood that pharmaceuticals transferred to an inappropriate 
location will have an adverse impact. Management strategies mitigate impacts o f unused 
pharmaceuticals so transferred or compensate for those impacts. Wide ranges of 
strategies are effective here. For example, most pharmaceutical manufacturers have 
stewardship standards and practices for their products. With some overlap of a stage three 
intervention, Pfizer maintains a Global Environment, Health, and Safety Policy that 
ensures contribution to “protect the natural and workplace environment by advising 
purchasers and users.. .about the safe handling and disposal o f our products (Pfizer,
2007)” . Bristol-Meyers Squibb acknowledges recent reports o f the detection of 
pharmaceutical residues in water systems (Bristol-Myers Squibb, 2008) and states the 
company’s support of further research. Merck has issued a public policy statement 
(Merck, 2007) promising continued collaboration with stakeholders to promote and
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support research in understanding the environment impacts o f pharmaceutical products. 
Indeed, working through the Pharmaceutical Research and Manufacturers of America 
(PhRMA), Merck and other pharmaceutical manufacturers, together with the US Fish and 
Wildlife Service and the American Pharmacists Association, support the “SMARxT 
DISPOSAL” program (US FWS, 2007) which strives to educate the public about proper 
use and handling of medications. An additional relevant note is the recent announeement 
by PhRMA of new guidelines regarding the interactions between healtheare professionals 
and pharmaeeutical manufaeturer representatives (PhRMA, 2008). These new guidelines 
are intended to remove the pereeption of influence on the prescription choices of the 
healthcare practitioner, an important overlapping factor for stage one interventions.
Resources should be directed for researeh and development o f reducing the 
environmental impacts of existing pharmaceuticals without compromising their 
therapeutie effieacy, or identifying alternate eompounds with equal therapeutie effieaey 
but less environmental impact. For example, Sanderson et al. (2004a) found modifying 
additives to be most toxie in risk assessment o f approximately 4,500 compounds, which 
included several pharmaceutical classes and their adjuvants. They recommended redueed 
use of these additives as a way of potential pollution prevention.
The Food and Drug Administration (FDA) requires the preparation o f an 
environmental risk assessments (US FDA, 1998) for most pharmaceuticals proposed for 
human use. However, eurrent assessments only require short-term tests that measure how 
much of a compound is required to kill an organism outright or stunt its growth in a 
matter of days. Longer studies may prove more useful. Furthermore, preparation o f this 
environmental assessment ordinarily is required unless the proposed action qualifies for a
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categorical exclusion (US FDA, 2008). A categorical exclusion from an environmental 
assessment is applied for newly formulated substances that would neither increase the use 
o f the active compound, increase the estimated concentration of the compound in the 
aquatic environment, nor would it change the distribution of the active compound, its 
metabolites, or its degradates in the environment. The rate o f new molecular entities 
released into the market has decreased over the past decade (AP, 2007). Generic switches 
and new formulations of pre-existing APIs dominate new drug approvals. Therefore, it 
may be fair to conclude that fewer environmental assessments are being required for new 
drug approvals in recent years.
Crucial to understanding the likelihoods and consequences of potential impacts of 
inappropriately transferred pharmaceuticals is identification and quantification of 
ultimate accumulation hotspots (landfills, sewage treatment systems). Chapter 3 and 
Ruhoy and Daughton (2008) outlined many locations where unused medication may be 
found. However, here is no ready source of data that addresses the quantity and frequency 
with which these drugs are inappropriately transferred to these and other locations, 
without which proper disposal procedures cannot effectively be enforced.
Pharmaceutical compounds that do enter the environment eventually are presented for 
treatment at STPs. Advanced sewage treatments, such as ozonation, can effectively 
remove many, if  not most, pharmaceutical compounds. However, not all STPs in the US 
have updated technology. Sewage treatment systems are resource intensive. They require 
a substantial investment of land, labor, and funds. Problematically, some compounds are 
refractory to even the most advanced technology. For example, Snyder et al. (2006) 
demonstrated greater than 90% removal o f target compounds using ozonation. However,
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meprobomate, an anxiolytic drug, and iopromide, tri-iodinated x-ray contrast agent, 
continued to be recalcitrant. Ying et al. (2007) found estrone and 17a-ethinylestradiol, 
both synthetic estrogens, to be persistent during different treatment technologies. Other 
studies by Snyder et al. (2007) demonstrate presence of several refractory compounds 
following different treatments, such as activated carbon and membrane bioreactors, but 
clearly display the efficiency of a multi-tiered treatment approach in the reduction of 
concentrations of pharmaceutical residues. Resources should be directed for research to 
upgrade and improve water treatment systems.
Crucial to effective mitigation/compensation is the understanding of the likelihoods 
and consequences o f impacts from each pharmaceutical agent. An appropriate protocol 
evaluates the potential effects of chronic, low-level exposure, as well as some specified 
mixture toxicity tests to account for the high probability of exposure to fnultiple 
pharmaceutical residues. Cooper et al. (2008) were able to rank pharmaceuticals in terms 
of risk o f exposure based on physical, chemical, and toxicological data. Cardiovascular, 
anti-microbials and central nervous system agents were highly represented.
Once signs and symptoms of exposure to environmental concentràtions of 
pharmaceutical compounds are identified, first-line treatment will most likely take place 
in the office of a healthcare practitioner. Treatment should be directed at the disease 
process assessed on an individual basis. As discussed for stage one intervention, 
treatment should be prudently and efficiently chosen. Alternative forms of treatment for 
toxicant exposure should be developed and considered. A recent article by McCoy (2008) 
addressed the benefits o f bentonite clay for treatment of pharmaceutical exposures.
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Finally, inappropriate transfers do not only result in low-dose human or ecosystem 
exposures; another problem is the effects of intentional or unintentional transfer to 
persons other than the prescription recipient. Drug diversion and abuse can have 
substantial public health consequences (NDIC, 2008). Law enforcement, from the local to 
international levels, represents one management strategy. Their role includes preventing 
drug diversion and punishing those who commit drug crimes. Another mitigation 
measure is treatment o f those who abuse and continue to seek drugs through criminal 
means. Strategies to mitigate this exposure include further training of law enforcement 
officials, increased funding o f social welfare programs, and improved addiction services
Conclusion
This chapter has outlined a broad risk management perspective on reducing the 
impacts of transfers of pharmaceuticals from households to inappropriate endpoints. The 
next steps for this approach include both developing the details of the risk management 
stages for households, as well as applying it to the other accumulation locations. 
Importantly, any future assessment that applies the four-stage risk management approach 
developed above should attend to the whole model in addition to its parts. The four-stage 
model is a heuristic, and sticking to it too strictly could obscure important feedbacks 
among the stages, and obscure the important dimension of time.
I have assessed existing conditions, as well as identified critical knowledge gaps, in 
the accumulation of unused pharmaceuticals in society. In addition, I have addressed the 
impacts and implications o f various strategies to modify the accumulation environment.
In the final chapter of this dissertation, I provide some brief conclusions about the ethical.
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resource and policy implications of changing the accumulation environment and the 
approach to prescription drugs.
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Academia, the public sector and the private sector increasingly prioritize research into 
the potential impacts of pharmaceutical residues, and effective means o f handling and 
discarding unused and unwanted medications. However, current data, ipfbrmation and 
models provide limited to guidance for improved management. This dissertation provides 
a foundation in terms of estimating types o f releases, the range of accumulation locations 
in society and mitigation strategies including pollution prevention and a four-stage risk 
management approach.
Several areas o f further research are critical to improving management strategies.
First, additional research is needed into fundamental information about sources and 
quantities o f accumulation and disposal. Second, considerable progress could be made in 
assessing the range of policy options for changing prescription, distribution and disposal / 
return practices.
Research is needed into the human behaviors that motivate physicians to prescribe 
medications, and patients to continue or discontinue medications that they have been 
prescribed. It will be incumbent upon society to examine these behaviors and motivating 
factors. Interaction between doctor and patient will probably require longer times in order 
for both parties to gain a better understanding o f the intent and motivation of the other. 
Yet if  we are able to use pharmaceuticals in the most efficient manner and not necessarily
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as a primary and reflexive eourse o f  treatment, and if  we eould provide more information 
and more guidance for patients through their treatment course, it is very likely we can 
reduce the demand, the supply, and the subsequent accumulation of unused and unwanted 
drugs.
The environment withstands and sustains insult and injury as a consequence to human 
ends. Its resilience cannot necessarily be relied upon for generations to come. In the 
Tragedy of the Commons, Garrett Hardin states “it is clear that we will greatly increase 
human misery if we do not, during the immediate future, assume that the world available 
to the terrestrial human population is finite”. Humans and their activities should be 
curtailed so that the ecological resources on which humans rely but often dismiss will 
continue to be in an appropriate state of health to deliver those services. Just as 
physicians may counsel patients to make better health and life choices so that the body 
may continue to serve them into older age, humans as a species should consider care for 
their environment and ecological landscape in order for the ecosystem to maintain 
effective balance.
Human activities must be guided by ecological rationality (Roling and Jiggins, 2001). 
The proposed recommendations for the curtailment of pharmaceutical consumption and 
behaviors can be appraised using a framework devised by Garry Brewer (1973) as 
outlined by Lee (2001). Specifically, the recommendations should be assessed based on 
its conceptual soundness, technicality, ethical limitations, and pragmatism.
Finally, there are more questions than answers regarding the presence of, and our 
exposure to, pharmaceuticals in the environment. We do know that they are consistently 
and continuously prescribed, dispensed, and all too often not consumed as intended. We
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do know these unwanted medications accumulate and find their way to an inappropriate 
location, ultimately the natural environment. There is probably danger to aquatic, 
amphibian, and terrestrial wildlife and there is potential risk to human health as well. 
Human health can be affected by both exposure to environmental contaminants and 
diversion, and subsequent misuse, of prescription drugs.
We don’t yet know to what extent the disposal of unused medication, as opposed to 
excretion, contributes to the pharmaceutical residues detected in water systems. 
Undoubtedly, both excretion and direct disposal result in pharmaceutical compounds in 
the water. However, consumption and disposal behaviors are more readily modifiable. 
Yet in order to justify diverting resources to help improve how we as a society prescribe, 
how we as patients consume and adhere, as we as producers become stewards of our 
product, and as we as consumers strive towards a more sustainable world through our 
actions, behaviors, and perceptions, we must research and collect information with regard 
to what drugs are accumulating at inappropriate locations, how often they accumulate, 
and how and when they are discarded.
As shown in chapter two, coroner offices are a ready source of information, but there 
are other opportunities for data collection as well, such as at the numerous take-back 
events and collection programs currently underway in cities across the nation or at 
healthcare institutions. The data will help us understand the drugs that most commonly 
remain unused, which will guide physicians, scientists, and policymakers in their efforts 
to curb the incidence of unused drugs and the presence of their residues in waters.
We are only beginning to investigate the role of prescribed drugs in our society and 
the result of their inappropriate presence. Pharmaceuticals as environmental pollutants
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are regulated, but our limited understanding of their origins, quantities, fate and transport 
leaves us uncertain about how effectively we have done so. Without this assessment, 
policies to minimize the exposure cannot be implemented. Once the policies can be 
implemented, they must be enforced with constant vigilance.
In addition, pharmaceuticals as primary treatment for patients may have become, in 
many instances, more reflexive and reactive than practical. Health care practitioners and 
patients alike have been bombarded with advertisement and information about the use of 
medications at a rate much greater than any methodical assessment and consideration can 
take place. This has led to greater prescription rates, excessive purchasing, and, 
ultimately, greater accumulation and eventual disposal.
The risk o f exposure exists, yet the consequence o f that risk has not yet been 
delineated. Pharmaceuticals are designed to be biologically active at low concentrations 
and were intended for a specified population (e.g., those suffering from a particular 
disease process). Pharmaceuticals were not designed nor intended for consumption by an 
unspecified population or for inappropriate accumulation and inappropriate transfer to 
inappropriate locations. The risk to life in close proximity to, and therefore directly 
dependent on, river and lake water has been partly established but the risk of life up the 
food chain has been underestimated since the exposure o f any particular compound has 
been found to be at very low concentrations, particularly in drinking water.
Exposure to therapeutic doses is not the concern. The concern remains that if 
inappropriate accumulation and transfer were to continue to occur unabated, the 
persistent exposure to low doses o f a multitude of biologically active compounds over 
decades could potentially result in detrimental effects on human health, especially on
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vulnerable populations such as infants and the immunocompromised. Methods o f risk 
mitigation and abatement cannot be calculated until the risk of inappropriate 
accumulation and transfer is established.
Many groups and organizations are working diligently on deciding the most prudent 
means o f disposal o f unwanted medications. Methods o f destruction are being 
investigated (i.e., Abburi et al., 2007; Snyder et al., 2006; Snyder et al., 2007), pilot 
collection events are taking place (i.e., IISG, 2007), and there is great discussion on what 
to instruct the consumer to do with inappropriately accumulated medication (i.e., US 
FWS, 2007). The excess of unused drugs needs to be dealt with, certainly. But the 
ultimate objective should remain no leftover drugs.
A complete absence of leftover drugs would require a concentrated effort to 
understand human behaviors and human genetics. A recent focus on hedlth, nutrition, and 
lifestyle advocate the incorporation of organic, whole foods, and supplementation to help 
prevent disease. Personalized medicine would allow for the most effective medication 
prescribed, but also the most efficient dose. This would be in contrast to the generic and 
mass prescribing for all having a certain physical complaint, as dictated by the many 
medicinal algorithms currently used by health care practitioners.
Personalized medicine, sometimes referred to as medical genetics or 
pharmacogenetics, strives to identify within each individual the genetic makeup that may 
or may not make them not only susceptible to disease, as done with screening tests, but
I
also to better predict the response to treatment. With a customized treatment strategy, a 
patient may be more apt to understand what the treatment is for and what improvements 
in their current health status they can expect. This would almost certainly improve
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compliance. Enhanced prescribing patterns and superior consumption behaviors would 
lead to improve health outcomes and a healthier environment.
Environmentally safe and yet accessible and affordable methods of disposal for 
pharmaceutical ingredients is a generally accepted ideal, as is the idea that we need to 
protect public health. Less general but still compelling is the need to change our drug- 
centric healthcare system, and to understand more holistically the relationship between 
human health and the environment. Our ecosystem is subject to unexpected and 
sometimes surprising change because o f unrecognized vulnerabilities. To evolve into a 
sustainable society we must closely examine our actions and our behaviors to evaluate 
the short- and long-term effects. We all play roles in our places in society, whether it is 
physician, policymaker, scientist, educator, consumer, or manufacturer. Each role has a 
responsibility and those responsibilities are not mutually exclusive. The final outcome 
will depend upon the intent of each role player and the extent to which each role is filled.
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